Townhall + Tv

Login

Healthcare

See All

Sean Browne, President and CEO, Xtant Medical Holdings Inc

Mr Karolis Rosickas, CEO, Regeneus Ltd

Stephen Gunnion, CEO, RELIEF THERAPEUTICS Holding

Iain Ross Executive Chairman, ReNeuron Group

Marjan Mikel, CEO, Respiri Ltd

Reggie Groves, CEO, REVA Medical Inc

Dr. Peter Suzdak, CEO of Rexahn Pharmaceuticals

Michael Johnson, CEO, Rhinomed Ltd

Karin Fischer, CEO, RLS Global

Ian Walters, CEO, SalvaRx Group Plc

Dr Thomas Meier CEO, Santhera Pharmaceuticals Holding Ltd

Tim Mitchell PhD FOUNDER & CEO, Sareum Holdings

Professor Lindy Durrant, CEO, Scancell Holdings P

Görgen Nilsson, CEO, ScandiDos

Peter Nählstedt. CEO, SenzaGen

Philip Toleikis, Ph.D., CEO and President, Sernova Corp

Greg Madison Chief Executive Officer, Shield Therapeutics

Matthew Hoskin, CEO, Sienna Cancer Diagnostics Ltd

Craig Tooman President and Chief Executive Officer, Silence Therapeutics

Eric Choo,Chief Executive Officer of Singapore O&G Ltd

Stuart Ashman, CEO, Skinbiotherapeutics

Mike Timoney, Chief Executive Officer for Smiles Inclusive (SIL)

Christopher J. Schaber, CEO, Soligenix Inc

Chris Seto Chief Executive Officer, Spectral Medical Inc

JOHAN EMILSSON Chief Executive Officer, Sprint Bioscience

Andrew Morris, CEO , SQI Diagnostics Inc

David Marsh Chief Executive Officer, Surgical Innovations Group

Richard Marsden Chief Executive Officer, Executive Director, Synairgen

Glynn Wilson, CEO, TapImmune Inc

Christian Behrenbruch, Managing Director & Group Chief Executive Officer, Telix Pharmaceuticals Ltd

Roger DuMoulin-White, CEO, Theralase Technologies Inc

Franck Mouthon, co-founder and CEO of Theranexus

Daniel Lee Chief Executive Officer, Tissue Regenix Group

Dr. Kunwar Shailubhai, CEO, Tiziana Life Sciences

Jarrod Ritchie, CEO, TPI Enterprises Ltd

Bill Welch, CEO of Trovagene, Inc.

Damian Marron, CEO, Txcell

Paul Wright, CEO, Universal Biosensors Inc

Prof. Rob Phillips, CEO of Uscom

Suzy Dilly, CEO, ValiRx

Jan Anders Karlsson, CEO, Verona Pharma

Ahmed Mousa CEO, Vicore Pharma Holding

Dr Stephen Snowdy, CEO, Visioneering Technologies Inc

Patricia Scheller, CEO of Viveve Medical, Inc.

Dr. Ralph Highnam, CEO, Volpara Health Technologies Ltd

Martin Amark, CEO, Xbrane Biopharma

Jeffrey F. Eisenberg Chief Executive Officer, Xenetic Biosciences Inc

Evy Lundgren-Åkerlund, CEO,

Per Andersson, Chief Executive Officer at Xspray Pharma

Emerging Drugs For Central Nervous System - Tim Dyer, CEO, Addex Therapeutics Ltd

Life-changing outcomes for patients worldwide - Wayne Paterson, CEO, Admedus Ltd

Advanced Oncotherapy's technology can slash costs of proton therapy cancer treatment - Nicolas Serandour, CEO, Advanced Oncotherapy PLC

AEterna Zentaris Inc is a specialty biopharmaceutical company - Klaus Paulini, PhD President and Chief Executive Officer, Aeterna Zentaris, Inc.

The vast global opportunity for the Maxigesic painkiller - Dr Hartley Atkinson Chief Executive Officer, Executive Director and Co-Founder, AFT Pharmaceuticals Ltd

Medical device, used in patients undergoing breast reconstruction following a mastectomy - Scott Dodson, CEO, AirXpanders Inc.

Taking the opportunity to give an update to the Company's shareholders - Søren Bregenholt CEO, Alligator Bioscience

Inflammation & Antibodies with Ampio Pharmaceutical - Michael A. Martino, Chief Executive Officer, Ampio Pharmaceuticals Inc

Company's successful listing on the exchange - Joe Wiley, CEO of Amryt Pharma

Christopher U. Missling, PhD, President & CEO of Anavex Life Sciences Corp.

Discusses what is unique about the company and what newsflow investors can expect - Michel Baijot, CEO of Asit Biotech

Avacta Group Plc making 'excellent progress' on lead programmes - Alastair Smith Chief Executive Officer, Avacta Group plc.

Take to the depths of the earth to experience how Bellevue Gold (ASX:BGL) operates - Darren Stralow Managing Director and CEO, Bellevue Gold Ltd

Interview with CEO Jonathan Royce regarding restructuring program -Jonathan Royce Chief Executive Officer, Bio-Works Technologies

Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE Executive Chair, biOasis Technologies Inc

Biomerica seeing their colorectal cancer screening test as a game changer - Zack Irani, CEO, Biomerica Inc

René C. Goehrum | Chairman, President & Chief Executive Officer, Biosyent Inc

How dermatology company is improving the lives of patients suffering from skin diseases- Matt Callahan Executive Director, Botanix Pharmaceuticals Ltd

Developing autologous stem cell therapies for debilitating neurodegenerative diseases - Lebovits, CEO, Brainstorm Cell Therapeutics Inc

Clive Dix BSc PhD HonFBPhS, CEO, C4X Discovery Holdings PLC

Enrolling patients in its coronavirus-induced lung damage treatment study - David Mazzo, CEO, Caladrius Biosciences Inc

Interview with David Reeves, MD - Calidus Resources Ltd

Talk about the partnerships in the success of Project LEILAC and the Calix technology - Phil Hodgson Managing Director & CEO, Calix Ltd

Cambridge Cognition acquires virtual clinical trial firm eClinicalHealth - Dr Matthew Stork Chief Executive Officer, Cambridge Cognition Holdings

Test target cancers that are difficult to diagnose - Panna Sharma, CEO, Cancer Genetics Inc

Rav Mlait, MBA CEO, Director, Cannabix Technologies Inc

Cantargia's CEO Göran Forsberg presents the company- Göran Forsberg, CEO, Cantargia

Developing transformative cell and exosome-based therapeutics to treat muscular diseases - Linda Marbán, Ph.D. Chief Executive Officer and Director, Capricor Therapeutics Inc

Predictive modeling driven behavioral healthcare services to health plans - Terren Peizer, Chairman & CEO of Catasys, Inc.

Ceapro using patented technology to disrupt the natural health care products - Gilles Gagnon, President and Chief Executive Officer, Ceapro

CEL-SCI Corp letter to shareholders details positive results from Phase 3 study of Multikine - Geert R. Kersten Director and Chief Executive Officer, CEL-SCI Corp

Cellmid expanding products, portfolio and markets - Maria Halasz , CEO, Cellmid Ltd

Development of a mobile system for managing type 1 diabetes - Eric Beard, Chairman and CEO of Cellnovo Group

Cello Health 'making good headway' with decent organic growth - Mark Scott, chief executive of Cello Health plc

Cerenis Therapeutics is specialized in research & development into HDL - Jean-Louis Dasseux, President and CEO of Cerenis Therapeutics

Checkpoint Therapeutics aiming to be phase 3 ready - James F. Oliviero President & Chief Executive Officer, Checkpoint Therapeutics Inc

Cipher Pharmaceuticals (TSX: CPH) Update with Craig Mull - CEO, Cipher Pharmaceuticals Inc

Commercialization of unique therapeutic products in adjunctive cancer care with a focus on infectious diseases. - Leonard Mazur, CEO, Citius Pharmaceuticals

CEO TALK - Yakov Kogan, CEO, Cleveland BioLabs

Eduardo Baviera Sabater, CEO, Clinica Baviera

Interview with Dan Mogren, CEO - Clinical Laserthermia Systems

An overview of Cocrystal’s core technology and applications in development - JAMES J. MARTIN Co-Chief Executive Officer and Chief Financial Officer, Cocrystal Pharma Inc

Emerging class of drugs for the treatment of chronic and age-related diseases - JOSEPH J. SARRET, M.D., J.D. Chief Executive Officer and Director, CohBar Inc

Release financial number showing more strong sales numbers - Jamal Rushdy, Chief Executive Officer, Collagen Solutions PLCC

DR. DAVID BURTON Executive Chairman, CEO, Compumedics Ltd

Talk about the company's joint venture to expand Positron Emission Tomography (PET)S - teven J. Mento, CEO, Conatus Pharmaceuticals

Jianyu Yang Chairman of the Board and Chief Executive Officer, Concord Medical Services Holdings Ltd

Invest to get the best income and growth - George Boubouras , MD, Contango Asset Management

Corline Biomedical at Pareto Securities' Health Care Conference - Henrik Nittmar , CEO, Corline Biomedical

Working on Infection Protection and Preventing the Global Expansion of Antimicrobial - Joe Todisco, CEO of CorMedix

Boaz Wachtel, CEO, Creso Pharma Ltd

Forward looking statements about Cyclacel Pharmaceuticals, Inc. - Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc.

Expansion of PET diagnostics business opportunities - James McBrayer, CEO, Cyclopharm Ltd

Cynata completes strategic review of development portfolio - Dr Kilian Kelly Chief Executive Officer and Managing Director, Cynata Therapeutics Ltd

Destiny Pharma's nasal spray project already delivering - Neil Clark, CEO, Destiny Pharma

Diffusion Pharmaceuticals Inc. Overview - David Kalergis, CEO, Diffusion Pharmaceuticals

e-Therapeutics PLC using its drug discovery platform - Jonny Wray, CTO, E-Therapeutics PLC

Eden Research signs new Mevalone distribution deal- Sean Smith, CEO, Eden Research PLC

Elixinol Global 'only company in the sector to list a profit - Paul Benhaim, Executive director & CEO, Elixinol Global Ltd

Keith Byrne, Ellex Medical Lasers Ltd

Ellex Medical Lasers - a South Australian Health-tech success - Kara Cannon, CEO of Enzo Biochem, Inc.

Interview with Pål Ryfors (CEO, Episurf Medical) - Pål Ryfors, CEO, Episurf Medical

Ergomed in robust shape as it continues to perform 'above expectations' - Dr Miroslav Reljanović Executive Chairman, Ergomed PLCE

Gil Beyen explains how Graspa works, its benefits and its other potential applications. - Gil Beyen, CEO, Erytech Pharma

Saundra Pelletier, CEO, Evofem Biosciences

ExpreS2ion Biotechnologies | Company presentation by CEO Bent U. Frandsen - Bent U. Frandsen, Chief Executive Officer, ExpreS2ion Biotech Holding

Dr Christian Behrenbruch, Executive Director, Factor Therapeutics Ltd

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment - Markku Jalkanen, CEO of Faron Pharmaceuticals Limited

Fibrocell Science - Company Presentation - David Pernock, Chairman & CEO, Fibrocell Science Inc

Focused on becoming a platform of life services for older adults - Katie Potter, president and chief executive officer, Five Star Senior Living Inc.

Fortress Bio | Benzinga Healthcare Small Cap Conference - Dr. Lindsay A. Rosenwald - Chairman, President, & CEO, Fortress Biotech Inc.

Fusion Antibodies presents at the Proactive One2One Investor Conference - Adrian Kinkaid, CEO, Fusion Antibodies PLC

1:03 / 7:30 • Key Successes Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales - James Barder, CEO, Futura Medical

G Medical Innovation : Connecting your health to your smartphone - Dr. Yacov Geva CEO, G Medical Innovations Holdings Ltd

James Czirr, Executive Chairman of Galectin Therapeutics, Inc.

Detecting infectious diseases in high-throughput lab workflows - John Melki, CEO, Genetic Signatures Ltd

Genetic Technologies embraces global vision for genomic-integrated healthcare - Simon Morriss, CEO, Genetic Technologies Ltd

Overview of the competitive advantages of Genkyotex’s products - Mr Elias Papatheodorou, CEO, GenKyoTex

Hamilton Thorne brings its laser technology human fertility - David Wolf, President and CEO of Hamilton Thorne Ltd.

Heat Biologics forms partnership with Waisman Biomanufacturing for coronavirus vaccine - Jeff Wolf, CEO, Heat Biologics Inc

Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy - Prof. Dr. Andreas Pahl Chief Executive Officer, Heidelberg Pharma

Diving Deeper Into the Background CEO -Dane C. Andreeff President and Chief Executive Officer , Helius Medical Technologies Inc

Forward looking statements about Helix BioPharma Corp - Heman Chao, PhD, Managing Partner of Helix BioPharma Corp.

ANTTI VUOLANTO Chief Executive Officer, Herantis Pharma Oyj

Commercializing products in the musculoskeletal segment of the marketplace - Adam Gridley, President and CEO, Histogenics Corp

Explained the rational for the sale of shares in hVIVO PLC- Cathal Friel, Chairman, Hvivo

Jean-Christophe Rain, PhD CEO and CSO, Hybrigenics

Alan Beasley, CEO, Hydroponics Company Ltd

Martin Brenner, DVM, Ph.D. CEO, Ibio Inc

Johan Wäborg CEO, Iconovo

Paul McDonald Chief Executive Officer, IDT Australia Ltd

Carlos de Sousa, CEO, Immunicum

Tim McCarthy FCCA, MBA Chief Executive Officer, ImmuPharma PLC

Steven Lydeamore Chief Executive Officer, Immuron Ltd

MARC VOIGT Executive Director & Chief Executive Officer, Immutep Ltd

Leslie Chong, CEO & Managing Director, mugene Ltd

Frederic Ors, CEO of IMV Inc.

Jenny Sundqvist, CEO, InDex Pharmaceuticals Holding

Staffan Strömberg, Ph.D. CEO, Infant Bacterial Therapeutics

Adelene Pewrkins, CEO, Infinity Pharmaceuticals Inc

Richard DiIorio Chief Executive Officer, InfuSystem Holdings Inc

Eric A. Adams, MIBS Chief Executive Officer & President, InMed Pharmaceuticals Inc

Neil Campbell, CEO, Inspiration Healthcare Group

DR. BERNARD COURTIEU CHIEF EXECUTIVE OFFICER, Integragen

Andre Godin, CPA, CA., President and Chief Financial Officer, Intelgenx Technologies Corp

Frédéric Cren Chief Executive Officer, Inventiva

Mr Thian Chew Executive Chair and CEO, Invion Ltd

Tom Ulich, CSO, InVivo Therapeutics Holdings Corp

Will Martin President and CEO, Irras

Anders Rabbe, CEO, Isofol Medical AB (publ)

Lori Woods, CEO of Isoray, Inc.

Giulio Cerroni CHIEF EXECUTIVE OFFICER, IXICO PLC

Andrew Sudholz, CEO, Japara Healthcare Ltd

Mark Iwicki, chairman and CEO, Kala Pharmaceuticals Inc

Peter Selin, CEO, Kancera

Viktor Drvota Chief Executive Officer, Karolinska Development

Dr John Friend Chief Executive Officer, Kazia Therapeutics Ltd

Jesper Wiklund, CEO, Klaria Pharma Holding AB (publ)

Arnab Basu, Chief Executive Officer, Kromek Group

Joost de Bruijn, CEO, Kuros Biosciences

Arthur Bedrosian, CEO, Lannett Company Inc

Brent Barnes, CEO, LBT Innovations Ltd

Karen Aiach, CEO, Lysogene

Mike Lampron Chief Executive Officer,Mach7 Technologies Ltd

Michael Castagna, PharmD Chief Executive Officer, Maternus Kliniken

Jerome D. Jabbour Chief Executive Officer, Matinas BioPharma Holdings Inc

Sacha Loiseau, Ph.D. Chief Executive Officer, Mauna Kea Technologies

Maher Masoud President and CEO, MaxCyte Inc

Dr Stuart Quin, CEO of Medica Group PLC

Fahar Merchant, PhD PRESIDENT AND CHIEF EXECUTIVE OFFICER, Medicenna Therapeutics Corp

Albert Friessen, Chair & CEO, Medicure Inc.

Jens Lindberg, CEO, Medivir

Sean Hall, CEO, Medlab Clinical Ltd

Dr. Denise Scots-Knight Chief Executive Officer, Mereo BioPharma Group

Stephen Stamp, CEO & CFO, Midatech Pharma P

Jan Adriaan (Arjan) Haverhals Chief Executive Officer and President, Milestone Scientific Inc

Jason Conroy, CEO, MMJ Phytotech Ltd

Anna Ljung, CEO , Moberg Pharma AB (publ)

Dr Mariola Söhngen, CEO, Mologen

Michael Knaap Chief Executive Officer and Managing Director, Monash IVF Group Ltd

Paul R. Gudonis Chairman & Chief Executive Officer, Myomo Inc

Brian Murphy Chief Executive Officer and Director, NanoVibronix Inc

Dr Anil Diwan, CEO, NanoViricides Inc

Michael Goldberg, President & CEO of Navidea Biopharmaceuticals, Inc.

Ilian Iliev, CEO, NetScientific

Richard Garr, President & CEO of Neuralstem Inc

Jon Pilcher, CEO, Neuren Pharmaceuticals Ltd

Erik Kinnman, CEO, NeuroVive Pharmaceutical

Stefan Weber, CEO, Newron Pharmaceuticals

Michele Garufi, CEO, Nicox

Harry Fleming, CEO, Nobilis Health Corp

Moritz F. Jäger,CTO of Northern Bitcoin

David Allmond, CEO, Novacyt

Dr Greg van Wyk, CEO, Noxopharm Ltd

Aram Mangasarian, CEO of NOXXON Pharma

Jesse Ledger, Chief Executive Officer, Nuvo Pharmaceuticals Inc.

Francois Martelet, CEO, Oasmia Pharmaceutical

Antony Mattessich, President & CEO, Ocular Therapeutix

Colin King, CEO, Omega Diagnostics Group

Adam Hill, CEO, Oncimmune Holdings

William Annett, CEO, OncoCyte Corp

Brad Thompson CEO of Oncolytics Biotech Inc.

Punit Dhillon, President & CEO of OncoSec Medical

Daniel Kenny, CEO, Oncosil Medical Ltd

Judith Greciet , CEO, Onxeo

Megan Baldwin, CEO, Opthea Ltd

Stephen Patrick, CEO, OptiBiotix Health

Dr Camile Farah Chief Executive Officer and Managing Director, Optiscan Imaging Ltd

Nikolaj Sørensen, CEO, Orexo

Vered Caplan, CEO at Orgenesis Inc.

Anders Hinsby, CEO of Orphazyme

Paul Anderson, CEO, Orthocell Ltd

Dr Nicolas Poirier , CEO, Ose Immunotherapeutics

Mike McCormick, CEO, Osprey Medical Inc

Dr. Chris Hart, Founder, and Chief Executive Officer, Oventus Medical Ltd

Christian Hoyer Millar, CEO, Oxford Biodynamics P

Patrik De Haes, CEO, Oxurion

David Darling, CEO, Pacific Edge Ltd

Phil McKenzie, CEO, Pacific Smiles Group Ltd

Dr. Donna Skerrett, CEO, Paradigm Biopharmaceuticals Ltd

Dr James Campbell, CEO, Patrys Ltd

Bert Liang, CEO, Pfenex

Gary Phillips, CEO, Pharmaxis Ltd

David Solomon, CEO of Pharnext

Stephanie Unwin, CEO, Phylogica Ltd

Fulvio Citaredo, CEO di Pierrel Spa

Lloyd Diamond, CEO, Pixium Vision S

Zami Aberman, CEO, Pluristem Therapeutics Inc

Christopher von Jako, CEO, Polarean Imaging

Dr. Ian Walters, CEO, Portage Biotech Inc

Rick Van Kirk, CEO of Pro-Dex, Inc

Dr Konrad Glund, CEO, Probiodrug

Pierre Laurin, CEO, ProMetic Life Sciences Inc

Dr. Elliot Goldstein, President and CEO of ProMIS Neurosciences

Jonas Ekblom, CEO of Promore Pharma

Dror Bashan, CEO, Protalix Biotherapeutics Inc

Dr. Richard Lipscombe, Managing Director, Proteomics International Laboratories Lt

Dr Ng Chin Siau, Founder & CEO of Q & M Dental Group (Singapore) Ltd

Lionel Segard, CEO of Quantum Genomics

Alex Martin, CEO, Realm Therapeutics

Dror Ben-Asher, CEO of RedHill Biopharma Ltd

Lisa Anson, CEO, Redx Pharma

J.J. Finkelstein, President and CEO of RegeneRx Biopharmaceuticals, Inc.

Pfizer

The pandemic has shone a light on the UK's life sciences sector and the important role of biotechnology|Jason C. Foster, MBA , CEO OF ORI BIOTECH

How the organisation currently works to support around 100 companies, where membership enables start-up companies|Ketil F. Widerberg , CEO OF OSLO CANCER CLUSTER

We provide patient matched, natural, and resorbable bone implants to reduce complications|Thea Wulff Olesen , CEO OF OSSIFORM

Partnerships with Industry and Venture Capitalist Firms: DDI partners with pharmaceutical, biotech and venture capital companies to bridge the gap|David E Cohn, MD , CEO OF OSU DRUG DEVELOPMENT INSTITUTE

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth|Tarek Rabah , CEO OF OTSUKA AMERICAPHARMACEUTICAL INC

The trend of big pharma brainpower moving to smaller firms to enable them to spend more time on innovation| Jeremy M. Levin, D.Phil, MB Bchir, CEO OF OVID THERAPEUTICS

Unveils Cutting-Edge AI Solutions for Cancer Treatment Research on BFM Business| Thomas Clozel, MD , CEO OF OWKIN

Dealing with a start up Bio Tech company working on Pancreatic Cancer with GP 2250 and other cancer applications|Greg Bosch , CEO OF PANAVANCE THERAPEUTICS INC

The EDV is proving safe and effective across a number of late-stage, intractable cancers like pancreatic cancer and mesothelioma| Dr Jennifer MacDiarmid , CEO OF ENGENEIC

How Engine Biosciences integrates machine learning, high-throughput biological experimentation, and innovative chemistry to decipher biology and develop new medicines for patients|Jeffrey Lu , CEO OF ENGINE BIOSCIENCES

Involvement inventing the breast cancer drug Herceptin and discussed the investment offering for his latest therapeutic development company|H. Michael Shepard , CEO OF ENOSI THERAPEUTICS

Gives us an update on what he's been busy with and why there hasn't been a new episode for a few weeksDr James R. McIlroy , CEO OF ENTEROBIOTIX

KNect365 Life Sciences about the company she co-founded as the latest spinout of Cold Spring Harbor Laboratory|Maria Luisa Pineda , CEO OF ENVISAGENICS, INC

Biofuels: A Sunshine Opportunity for the Green Growth|Marilyn Bruno , CEO of Aequor Inc

Acrux has developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe|Michael Kotsanis , CEO of Acrux Limited

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease|Stephan Jackman , Chief Executive Officer at Alzamend Neuro

Chatham Rock Phosphate is the custodian of New Zealand's only material resource of ultra-low cadmium, environmentally friendly pastoral phosphate fertiliser|Chris Castle, President and CEO of Chatham Rock Phosphate Limited

Insights into the Resilient Performance of the Tanker Industry Amidst the Pandemic|WONG KEVIN, Director of PT Buana Lintas Lautan Tbk

A Conversation with Kimberly Carlson, CEO & CFO of Mushrooms Inc. – Pioneering Sustainability through Mycelium Innovation | KIMBERLY CARLSON, CEO AND CFO OF MUSHROOM INC

Xspray Pharma CEO Presents at Naventus Life Science Summit 2021 | PER ANDERSSON , CEO OF XSPRAY PHARMA AB

Xtant Medical (NYSE: XTNT) CEO Sean Browne Discusses Surging Demand and Growth Strategy Amid Successful Biologics Product Launches | SEAN BROWNE , CEO OF XTANT MEDICAL HOLDINGS INC

Life Science Capital Strategies in Challenging Markets | Jonathan Gertler, CEO of Back Bay life science advisors

Ovation Science Inc. CEO Terry Howlett Talks Innovations in CBD/THC Products and Invisicare® Skin Delivery Technology| TERRY HOWLETT , CEO OF OVATION SCIENCE, INC

Gain Therapeutics and Zentalis Pharmaceuticals Forge Innovative Partnership in Multi-Target Oncology Drug Discovery and Development | KIMBERLY BLACKWELL, MD , CHIEF EXECUTIVE OFFICER OF ZENTALIS PHARMACEUTICALS INC

Unveiling Innovation at Zentiva's Cutting-Edge R&D Center: Pioneering Pharmaceutical Breakthroughs for a Healthier Tomorrow | STEFFEN SALTOFTE , CHIEF EXECUTIVE OFFICER OF ZENTIVA SA

Taking Care of Present Issues While Gazing Forward | NICHOLAS GREEN, CEO, AVID BIOSERVICES INC

Generating immune cells from induced pluripotent stem cells to combat a variety of malignancies | MR. CHOO CHEE KONG, CHAIRMAN AND DIRECTOR, CYTOMED THERAPEUTICS

Zymeworks CEO Ali Tehrani on Biotech Success and Challenges | ALI TEHRANI, PH.D. , PRESIDENT & CHIEF EXECUTIVE OFFICER OF ZYMEWORKS INC

Zynerba Pharmaceuticals Bolsters IP Portfolio for Zygel, Revolutionary Cannabidiol Clear Gel with Enhanced Transdermal Delivery| ARMANDO ANIDO , CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER OF ZYNERBA PHARMACEUTICALS, INC

ZyVersa Therapeutics Pioneer Breakthroughs in Inflammatory and Kidney Disease Treatment | STEPHEN C. GLOVER , CO-FOUNDER, CHIEF EXECU TIVE OFFICER, AND CHAIRMAN OF ZYVERSA THERAPEUTICS INC

Navigating Complex Pipelines and Scalable Manufacturing Platforms| ALESSANDRO MASELLI , CHIEF EXECUTIVE OFFICER OF CATALENT

Biogen CEO on Revolutionizing Drug Development for Rare Diseases with n-Lorem | CHRISTOPHER A. VIEHBACHER, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF BIOGEN

Neurosciences Avidity - Myotonic Dystrophy | SARAH BOYCE, PRESIDENT & CHIEF EXECUTIVE, FICER OF AVIDITY BIOSCIENCES INC

Global Commerce with Kathy Ireland®-Advances in Incontinence Management with Dr. Karen Noblett | Raymond W. Cohen, CHIEF EXECUTIVE OFFICER, AXONICS INC

Clarivate assists clients in finding, safeguarding, and promoting their inventions | JONATHAN GEAR, CEO, Clarivate PLC

Stock News Now for Ascletis Pharma Inc. (HKEX: 1672) | Jinzi J. Wu, PhD , CEO, ASCLETIS PHARMA INC

Online viralgen new facilities sub-eng sin band 1 | Gustavo Pesquin, CEO, ASKLEPIOS BIOPHARMACEUTICAL, INC.

Bill Rancic and Mark Reisenauer Talk About the C3 Award for Cancer Innovation | Mark Reisenauer, PRESIDENT, ASTELLAS PHARMA US, INC

Financial results for the entire year 2021: Pascal Soriot, CEO | Pascal Soriot, CEO OF AstraZeneca INC

The goal of drug developer Atossa Therapeutics is to "transform the breast cancer paradigm." | Steven C. Quay, CEO, ATOSSA THERAPEUTICS INC

Pan-Amyloid Removal Therapeutics by Attralus: A Novel Approach to Systemic Amyloidosis | Mark Timney, CHIEF EXECUTIVE OFFICER, ATTRALUS

NC BioTech CEO Doug Edgeton on Life Sciences Innovations | DOUG EDGETON, PRESIDENT AND CEO OF NORTH CAROLINA BIOTECHNOLOGY CENTER

CEO Spotlight: Leadership Insights from Jason C. Foster of Ori Biotech | JASON C. FOSTER , CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR OF ORI BIOTECH

4D Pharma raises $40 million - Duncan Peyton, CEO, 4D Pharma

4D Pharma finds success for its Parkinson’s treatment - Duncan Peyton, CEO, 4D Pharma

4D pharma gets green light for phase I clinical trial of Parkinson's disease - Duncan Peyton, CEO, 4D Pharma

4D Pharma hopes to expand drug success to other areas - Duncan Peyton, CEO, 4D Pharma

4d pharma reveals 'phenomenal results' from early stage cancer trial - Duncan Peyton, CEO, 4D Pharma

Interview with Alan Clarke, CEO Abano Healthcare Limited

Dr. Hartmut Ehrlich, CEO, Abivax

EnterNext welcomes Abivax on Euronext in Paris - Dr. Hartmut Ehrlich, CEO, Abivax

Abivax seeks partners - Dr. Hartmut Ehrlich, CEO, Abivax

John Burt, chief executive of Abzena PLC

Per Persson, CEO of Acarix

Timothy Morris - CFO, Head of Business Development, AcelRx Pharmaceuticals Inc

Ed Gudaitis, President and CEO, Acerus Pharmaceuticals Corporation

Ed Gudaitis, President and CEO, Acerus Pharmaceuticals Corporation

Ed Gudaitis, President and CEO, Acerus Pharmaceuticals Corporation

AdAlta delivers positive Phase I Extension Study results - Tim Oldham, MD, Adalta Ltd

AdAlta Phase I Extension Study Results - Tim Oldham, MD, Adalta Ltd

Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it advances SAVR trial - Wayne Paterson, CEO, Admedus Ltd

Admedus Ltd proud to unveil its valves publicly for the first time in London - Wayne Paterson, CEO, Admedus Ltd

Admedus (ASX:AHZ) CEO Wayne Paterson interview

Admedus (ASX:AHZ) CEO Wayne Paterson podcast

Advanced Oncotherapy PLC on its proton beam therapy system - Dr Johnathan Farr , chief clinical officer at Advanced Oncotherapy

Advanced Oncotherapy now has the ammo to "democratise proton therapy", says CEO - Nicolas Serandou, CEO, Advanced Oncotherapy

Advanced Oncotherapy present research potentially offering 'powerful weapon to resistant cancers' - Jonathan Farr, Chief Clinical Officer, Advanced Oncotherapy

Company Overview: Aeterna Zentaris Inc. - David Dodd, CEO, Aeterna Zentaris Inc.

Dr. Tim Rodell, M.D., CEO and Director at Aethlon Medical, Inc

AirXpanders Inc.(ASX:AXP) sales and product update - Scott Dodson, CEO,AirXpanders Inc

Mad Money: Aurinia Pharmaceuticals CEO: Speculative Salvation? | Peter Greenleaf, CEO, AURINIA PHARMACEUTICALS INC

Q&A with Carbios Chief Executive Officer Emmanuel Ladent | EMMANUEL LADENT, CHIEF EXECUTIVE OFFICER, CARBIOS

Day 4 of the 2024 Mining Indaba: Keamogetswe Mpofu's Mechanical Engineering PIT | DR. NOMBASA TSENGWA ,CHIEF EXECUTIVE OFFICER (MEMBER SOCIAL, ETHICS AND RESPONSIBILITY COMMITTEE), EXXARO RESOURCES LTD

Alimera Sciences is a pioneering presence in the realm of ophthalmology | RICK EISWIRTH, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALIMERA SCIENCES INC

Chief Technology Officer Michael Tolentino, MD, is with Aviceda Therapeutics. | Mohamed Genead, MD, CHIEF EXECUTIVE OFFICER, AVICEDA THERAPEUTICS INC

An Exploration into Autoimmunity | Molly Murray_CAE, CEO OF AUTOIMMUNE ASSOCIATION

AVACTA's Chief Scientific Officer, Dr. Fiona McLaughlin | Alastair Smith, CEO, AVACTA THERAPEUTICS.

Executive Highlights Edwina Payne of Avanos Medical | JOSEPH F. WOODY, CEO OF AVANOS MEDICAL INC

Creating the Next Wave of Cancer Treatments for Patients | Athena Countouriotis, M.D. Chairperson, Avenzo Therapeutics

2020 will be a pivotal year for Arcturus Therapeutics as a corporation | Joseph E. Payne, CHIEF EXECUTIVE OFFICER, ARCTURUS THERAPEUTICS LTD

Executive interview with Basilea Pharmaceutica | David Veitch, CHIEF EXECUTIVE OFFICER, BASILEA PHARMACEUTICA INTERNATIONAL LTD

Akers Biosciences : It’s now all about execution - Ray Akers, co-founder and executive chairman of Akers Biosciences

Akers Biosciences Inc to be cash generative in second half - Raymond Akers, Executive chairman of Akers Biosciences Inc

Alimera Sciences - RICK EISWIRTH President and Chief Executive Officer, Alimera Sciences Inc

Allergy Therapeutics to sniff out more M&A deals - Manuel Llobert, CEO, Allergy Therapeutics

Allergy Therapeutics says US preparations are underway which include two pivotal trials - Manuel Llobert, CEO, Allergy Therapeutics

Allergy Therapeutics - Nick Wykeman, CFO

Alligator Bioscience - CEO Statement - Søren Bregenholt , CEO, Alligator Bioscience

Alligator Bioscience restructuring as part of long-term strategy - Søren Bregenholt , CEO, Alligator Bioscience

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer - Søren Bregenholt , CEO, Alligator Bioscience

Alligator Bioscience at the ØU Lifescience Investor Conference, November 22, 2023 - Søren Bregenholt , CEO, Alligator Bioscience

Alligator Bioscience | May 2023 - Søren Bregenholt , CEO, Alligator Bioscience

aims to be an innovative drug discovery and development company - Michael A. Martino, Chief Executive Officer, Ampio Pharmaceuticals Inc

Michael A. Martino, Chief Executive Officer, Ampio Pharmaceuticals Inc

Paul Grint Discusses AmpliPhi Biosciences - Paul Grint, CEO, AmpliPhi Biosciences Corp

Amryt Pharma hail rocketing revenue growth 'we're a biotech that makes money - Joe Wiley, CEO, Amryt Pharma

Anatara Lifesciences with Proactive at ASX Small and Mid-Cap Conference - Steve Lydeamore, CEO, Anatara Lifesciences Ltd

Anatara Lifesciences transitions gut health focus from animals to humans - Steve Lydeamore, CEO, Anatara Lifesciences Ltd

Christopher U. Missling Ph.D. , CEO, Anavex Life Sciences Corp

Anders Hultman, CEO, AroCell AB (publ)

Avacta Group boss explains potential of its Affimer technology - Alastair Smith, CEO, Avacta Group Chief Executive Officer

Avita Medical CEO: Burn Care Advancements | Dr. Michael Perry, CEO, Avita Medical Ltd

BBS's company presentation , Ilkka Kangasniemi, CEO, BBS-Bioactive Bone Substitutes

Darren Stralow Managing Director and CEO, Bellevue Gold Ltd

Carl Syubbings, CEO, Benitec Biopharma Ltd

BerGenBio (BGBIO) is a clinical-stage biopharmaceutical company - Martin Olin , Chief Executive Officer, Bergenbio

Bio-Works CEO, Jonathan Royce, interview - Jonathan Royce Chief Executive Officer, Bio-Works Technologies

Bioasis Technologies forms 'exciting' licensing agreement with Chiesi Global Rare Diseases - Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE -Executive Chair, biOasis Technologies Inc

BioInvents's CEO Martin Welschof presents the company - Martin Welschof Chief Executive Officer, BioInvent International

Biophytis sees positive data from PHASE 2-3 COVA CLINICAL STUDY of Sarconeos - Stanislas Veillet , CEO, Biophytis

BioPorto discusses 'fantastic first half of the year' driven by antibodies and RUO NGAL Test sales - Peter Mørch Eriksen, CEO/Board Member,Bioporto

BioPorto CEO explains why he's expecting 2021 to be a 'pivotal year - Peter Mørch Eriksen, CEO/Board Member,Bioporto

BioPorto discusses 'fantastic first half of the year' driven by antibodies and RUO NGAL Test sales - Peter Mørch Eriksen, CEO/Board Member,Bioporto

BioPorto optimistic over FDA clearance for its NGAL kidney diagnostic test for use on children - Peter Mørch Eriksen, CEO/Board Member,Bioporto

Peter Mørch Eriksen, CEO/Board Member,Bioporto

Petter Bäckgren, CEO, Bioservo Technologies

René C. Goehrum President & Chief Executive Officer, Biosyent Inc

Biotec Pharmacon presentation - Christian Jorgensen, CEO, Biotec Pharmacon A

Thomas Lienard, CEO, Bone Therapeutics

BOT Investor Webinar | 26 September 2023 - Vince Ippolito Executive Chairman, Botanix Pharmaceuticals Ltd

Jesper Söderqvist, CEO, Boule Diagnostics

Dr. Gregory Bayer, CEO, Brain Resource

Cell & Gene Exchange, May 2017: BrainStorm Cell Therapeutics - Chaim Lebovits, CEO, Brainstorm Cell Therapeutics Inc

C4X Discovery Holdings PLC on expanding its portfolio - Clive Dix BSc PhD HonFBPhS, Interim Executive Chairman & CEO, C4X Discovery Holding

C4X Discovery signs potential $402mln deal - Clive Dix BSc PhD HonFBPhS, Interim Executive Chairman & CEO, C4X Discovery Holding

C4X Discovery Holdings PLC bags a billion molecules -Clive Dix BSc PhD HonFBPhS, Interim Executive Chairman & CEO, C4X Discovery Holding

C4X Discovery on €3m Sanofi milestone payment and pipeline of other partnerships -Clive Dix BSc PhD HonFBPhS, Interim Executive Chairman & CEO, C4X Discovery Holding

C4X Discovery CEO welcomes start of Indivior trial and outlines new coronavirus venture -Clive Dix BSc PhD HonFBPhS, Interim Executive Chairman & CEO, C4X Discovery Holding

The limitations of human heart transplant availability - Stéphane Piat, CEO of Carmat

CEL-SCI CEO Geert Kersten Exclusive May 2023 Interview - Geert Kersten , CEO, CEL-SCI Corp

Cellmid Limited to supply rapid diagnostic tests to help - Maria Halasz, CEO, Cellmid Ltd

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value - Jim Martin, Co-CEO and CFO, Cocrystal Pharma, Inc.

Cogstate Limited - Brad O’Connor Chief Executive Officer, CogState Ltd

Collagen Solutions Overview - Jamal Rushdy, Chief Executive Office, Collagen Solutions

Collagen Solutions released financial number showing more strong sales numbers - Jamal Rushdy, Chief Executive Office, Collagen Solutions

Bond repayment amendment to give Collagen Solutions 'greater flexibility to exploit opportunities' -Jamal Rushdy, Chief Executive Office, Collagen Solutions

ollagen Solutions 'well on track' with plans for CE Mark and first surgery - Jamal Rushdy, Chief Executive Office, Collagen Solutions

Collagen Solutions applies for European approval after successful ChondroMimetic study -Jamal Rushdy, Chief Executive Office, Collagen Solutions

Compumedics expects to be back in profit for FY23 - David Lawson, CFO, Compumedics Ltd

David Cutler CEO, Centric Health Corporation

Corline Biomedical - Naventus Healthcare Summit, May 10, 2022 - Henrik Nittmar, CEO at Corline Biomedical

Olivier Giré, Chief Operating Officer Specialty Pharma, Crossject

Oliver Schacht, CEO, Curetis

Innovative Targeted Therapies for Advanced Cancer - Spiro Rombotis, CEO, Cyclacel Pharmaceuticals

Cynata Therapeutics (ASX:CYP) CEO & MD Kilian Kelly

Dedicare - ABGSC Investor Days 8 mars 2022 - Krister Widstrom, CEO, Dedicare AB (publ)

Destiny Pharma's nasal spray project already delivering "more than hoped for" - Neil Clark , CEO, Destiny Pharma

Diamyd Medical | interview with CEO Ulf Hannelius

Dignitana 2020 Presentation - William Cronin, CEO Dignitana

Diurnal (DNL) - Martin Whitaker, CEO

Exclusive Interview with Doxa CEO Jan Edöcs at Geneva - Jan Edöcs, CEO, Doxa

Eden Research "very optimistic about how 2024 will look" - Sean Smith, CEO, Eden Research

Eden Research targets New Zealand wine grape market after receiving regulatory sign-off - Sean Smith, CEO, Eden Research

Sustainable Agriculture: Eden Research CEO Reveals Global Expansion Plans and Launch in California - Sean Smith, CEO, Eden Research

Eden Research aims to bring its sustainably-focused bio-pesticides to the US market - Sean Smith, CEO, Eden Research

Eden Research list in US to 'access world's largest capital markets' and seize opportunities - Sean Smith, CEO, Eden Research

Eden Research 'well positioned to growth consistently' -Sean Smith, CEO, Eden Research

Eden Research hails deal with US agriscience giant Corteva as the big news they've been waiting for -Sean Smith, CEO, Eden Research

Ekso Bionics Holdings, Inc EKSO CEO Jack Peurach on 2019 Results

Tomas J. Svoboda, CEO, Elanix Biotechnologies

Kathleen Skarvan, CEO, Electromed Inc

ExpreS2ion Biotech Holding - Bent U. Frandsen, Chief Executive Officer, ExpreS2ion Biotech Holding

Enzymatica presents positive in-vitro results | August 2023 - Claus Egstrand,CEO, Enzymatica AB (publ)

Interview with Pål Ryfors (CEO, Episurf Medical)

Ergomed in robust shape to keep delivering - Jonathan Curtain, CFO, Ergomed

Interest in Ergomed's blood thickener 'significant' - CEO Miroslav Reljanovic, Ergomed

Ergomed cheers 'very strong' performance in first half of 2022 -

Ergomed announce £25mln acquisition - Miroslav Reljanović, CEO, Ergomed

Evgen Pharma "very busy" at start of "exciting year" - Dr Huw Jones, CEO, Evgen Pharma

Interview with Jodie Gilmore, Global Orthopedic Business Director at Elos Medtech

Evgen Pharma "delighted" with cash position after promising first half - Dr Huw Jones , CEO, Evgen Pharma

Evgen Pharma talks through clinical milestones and financial results from its 2022 full year report - Huw Jones, CEO, Evgen Pharma

Executive interview – Dr Heikki Lanckriet, CEO, Expedeon

EyeGate Pharma Moving Fast Toward Commercialization - Stephen From , CEO, EyeGate Pharmaceuticals Inc

From the operating room to the C-suite in pharma - Jay S. Duker, MD President & CEO and Board Director, Eyepoint Pharmaceuticals Inc

Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals

Faron Pharmaceuticals Oy excited by green light for trials of promising anti-cancer treatment - Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals

Faron Pharmaceuticals CEO delighted with latest BEXMAB study findings - Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals

Faron Pharmaceuticals initiates second phase of BEXMAB study -Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals

Faron Pharmaceuticals kicks off second half with FDA announcement -Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals

Futura Medical continues global expansion with Latin America announcement - James Barder, Chief Executive, Futura Medical

Futura Medical "on track for a profit in 2025" after strong first half - James Barder, Chief Executive, Futura Medical

CEO Paul McDonald talks of the huge pipeline going forward - Paul McDonald Chief Executive Officer, IDT Australia Ltd

Immunicum | CEO interview, Erik Manting, CEO, Immunicum

ImmuPharma "absolutely delighted" to push on with new clinical trial -Tim McCarthy, FCCA, MBA - Chief Executive Officer, ImmuPharma

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments -Tim McCarthy, FCCA, MBA - Chief Executive Officer, ImmuPharma

Update from Genesis HealthCare System CEO & President Matthew J. Perry

Highlights Genetic Technologies (NASDAQ: GENE) -Simon Morriss, CEO, Genetic Technologies Ltd

Genetic Technologies building pathway to profitability - Simon Morriss, CEO, Genetic Technologies Ltd

Simon Morriss, CEO, Genetic Technologies Ltd

Genetic Technologies: Decoding the Genome and Unlocking its Value for Human Health - Simon Morriss, CEO, Genetic Technologies Ltd

Genetic Technologies embraces global vision for genomic-integrated healthcare -Simon Morriss, CEO, Genetic Technologies Ltd

GeNeuro SA (ENXTPA:GNRO) Executive Presentation -Jesús Martin-Garcia, Chief Executive Officer, Geneuro

GeNeuro homes in on ancestral viral genes to treat autoimmune diseases - Jesús Martin-Garcia, Chief Executive Officer, Geneuro

GeNeuro SA (ENXTPA:GNRO) Investor Presentation -Jesús Martin-Garcia, Chief Executive Officer, Geneuro

Jesús Martin-Garcia, Chief Executive Officer, Geneuro

Elias Papatheodorou, CEO of Genkyotex, tells us more about his relationship with the BioDiscovery team

Genovis | Fredrik Olsson, CEO, Genovis

Alexandre Fraichard, CEO, Genoway

Interview of Alexandre Fraichard, CEO of Genoway

Interview of Alexandre Fraichard, CEO, Genoway

GenSight Biologics - Magali Taiel Chief Medical Officer, Gensight Biologics

GHP Specialty Care Presentation - Daniel Ohman, CEO, GHP Specialty Care AB (publ)

GTX Corp; Introducing the CEO and New Video Updates - Patrick Bertagna , CEO, GTX Inc

Johan Ek, CEO, Handicare Group

Helius Medical Technologies; Discussing the Stock & Similar Comparable Companies - Dane C. Andreeff President and Chief Executive Officer , Helius Medical Technologies Inc

Helius Medical Technologies; An Introduction to the Company Itself - Dane C. Andreeff President and Chief Executive Officer , Helius Medical Technologies Inc

Helius Medical Technologies; Diving Into Some Exciting Pivotal Company Updates -Dane C. Andreeff President and Chief Executive Officer , Helius Medical Technologies Inc

Hemcheck | CEO interview, Joen Averstad, CEO, Hemcheck

Nordic Congress 2018: Herantis Pharma CEO Pekka Simula - Pekka Simula, CEO, Herantis Pharma

hVIVO secures fresh contract to round out "wonderful" year - Yamin ‘Mo’ Khan, Chief Executive Officer, Hvivo PLC

hVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale - Cathal Friel, Chairman, Hvivo

Kromek Group rounds off "landmark year" - Arnab Basu, Chief Executive Officer, Kromek Group

Kromek Group boss Arnab Basu tells investors to expect 'robust news flow' - Arnab Basu, Chief Executive Officer, Kromek Group

Kromek Group: Interview with CEO Arnab Basu on group prospects - Arnab Basu, Chief Executive Officer, Kromek Group

Rick Carreon, Managing Director & Chief Executive Officer, ImpediMed Ltd

Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO, Imugene Ltd - Leslie Chong | CEO & Managing Director, Imugene Ltd

Imugene progresses onCARlytics solid tumour trial to combination arm - Leslie Chong | CEO & Managing Director, Imugene Ltd

Imugene Ltd MD and CEO shares with JustStocks plans for Phase 1 onCARlytics Combination Study - Leslie Chong | CEO & Managing Director, Imugene Ltd

Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial - Leslie Chong | CEO & Managing Director, Imugene Ltd

Imugene sees positive early signals in Phase 1 VAXINIA study - Leslie Chong | CEO & Managing Director, Imugene Ltd

Imugene Commences new PD1-Vaxx Bowel Cancer Trial - Leslie Chong | CEO & Managing Director, Imugene Ltd

CEO presentation AGM2021 - Andreas Andersson, CEO, Intervacc

IsoRay, Inc ISR CEO Lori Woods on 2020 Results - Lori Woods , CEO, IsoRay Inc

Jaguar Health CEO Lisa Conte

Japara Healthcare (ASX:JHC):Andrew Sudholz , CEO -Andrew Sudholz , CEO, Japara Healthcare Ltd

Japara Healthcare (JHC): Andrew Sudholz, Chief Executive Officer & Executive Director

Kancera at Carlsquare Nordic Life Science Investor Day 6 Dec. 2023 - Peter Selin, CEO, Kancera

Kancera – 5 mar 2024 - Peter Selin, CEO, Kancera

Kancera -27 november 2023 - Peter Selin, CEO, Kancera

Mike Lampron – CEO - Mach7 Technologies

Michael K. McGarrity Chief Executive Officer, Director, MDxHealth

Stuart Quin Chief Executive Officer, Medica Group

Fahar Merchant, PhD PRESIDENT AND CHIEF EXECUTIVE OFFICER, Medicenna Therapeutics Corp

Medicure Inc (MPH-TSX.V) Interview with CEO Dr. Albert Friesen - Albert D. Friesen, PhD. Chief Executive Officer and Chairman of the Board, Medicure Inc

Medicure, Inc MCUJF CEO Albert Friesen on 2020 Results - Albert D. Friesen, PhD. Chief Executive Officer and Chairman of the Board, Medicure Inc

Mr. Peter Crosby, President and CEO of Mainstay Medical

Global Health Leadership in the Private Sector - a conversation with Medistim CEO Kari E. Krogstad - Kari E. Krogstad, CEO, Medistim

Interviews Jens Lindberg, CEO Medivir at the Swiss Nordic Bio conference in Zürich, Switzerland - Jens Lindberg, CEO, Medivir

Medivir presentation - Jens Lindberg, CEO, Medivir

Medivir - ABGSC Life Summit May 18 2022 - Jens Lindberg, CEO, Medivir

Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities -Dr Sean Hall, CEO, Medlab Clinical Ltd

Micro-X (ASX:MX1): Peter Rowland, Managing Director, Micro-X Ltd

MicroBix (MBX.T) CEO, Cameron L. Groome, talks antigens

Moberg Pharma | Interview - Anna Ljung, CEO, Moberg Pharma AB (publ)

CEO Anna Ljung presents Moberg Pharma - Anna Ljung, CEO, Moberg Pharma AB (publ)

Anna Ljung, CEO, Moberg Pharma AB (publ)

Eric Poma, CEO of Molecular Templates

US companies set the benchmark for Motif Bio - Graham Lumsden, chief executive of Motif Bio PLC

Miguel Sieler, CEO, Neovacs

Neovasc uses conference to announce positive interim clinical data from Neovasc Reducer use - Bill Little, COO, Neovasc Inc

Mike McCormick President & CEO, Osprey Medical Inc

Update with Orgenesis Inc. (OTCQB: ORGS) | Vered Caplan, CEO, Orgenesis Inc

Orgenesis signs deal with Accellix, invites Academy Award winner on Scientific board - Vered Caplan, CEO, Orgenesis Inc

NetScientific changes "really paying off" - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

What makes CEOs tick?' with Dr Ilian Iliev, CEO of NetScientific - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

NetScientific "well positioned for growth" when venture capital market turns - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

NetScientific PLC's purchase of interest in Vortex Bio showcases “deep stake” transatlantic strategy - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

NetScientific PLC actively driving its investee companies forward - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

NetScientific PLC present at the Proactive One2One Investor Forum - January 26th 2023 - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

NetScientific PLC discusses FDA fast-track of its portfolio company's cancer treatment - Dr. Ilian Iliev CHIEF EXECUTIVE OFFICER, Netscientific

ASX Small & Mid Cap Conference: Neuren Pharmaceuticals Limited - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd

Biotech Unlocked - NEUREN PHARMACEUTICALS - ASX:NEU - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals CEO Jon Pilcher discusses on Phase 3 LAVENDER Rett Syndrome trial. - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd

Erik Kinnman, CEO, NeuroVive Pharmaceutical

Catherine Turkel Discusses Pharmacy School and Novus Therapeutics - Catherine Turkel, President, Novus Therapeutics Inc

Noxopharm CEO talks Veyonda orphan drug designation from US FDA - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd

Noxopharm details science-driven strategy in new investor presentation - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd

Noxopharm hails new Sofra™ drug inflammation results - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd

Noxxon CEO discusses partners and cancer combinations - Aram Mangasarian , CEO, NOXXON Pharma

Aram Mangasarian , CEO, NOXXON Pharma

Interview with Aram Mangasarian, CEO of NOXXON

Aram Mangasarian , CEO, NOXXON Pharma

Francois Martelet, CEO, Oasmia Pharmaceutical

Oncimmune's strategic pivot aims for robust growth in 2024 - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings

ONCIMMUNE HOLDINGS PLC - Investor Presentation - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings

Oncimmune "relaunch" already delivering results - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings

ONCIMMUNE HOLDINGS PLC - Strategy Update - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings

Onconova Therapeutics featured on Worldwide Business - Dr. Steven Fruchtman, CEO, Onconova Therapeutics Inc

OptiBiotix Health delighted to launch range in India through Apollo - Stephen Patrick O'Hara CEO / Founder, OptiBiotix Health

OptiBiotix secures exclusive manufacturing agreement for CE marked SlimBiome - Stephen Patrick O'Hara CEO / Founder, OptiBiotix Health

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020 - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd

Pharmaxis welcomes positive interim data for Phase 2 cancer trial - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd

Pharmaxis extends scarring collaboration after encouraging results - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd

Orthocell raising $3.5 million; adds heavy hitters to register - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Orthocell on the cusp of significant growth - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Orthocell signs defining licence and distribution agreement - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Orthocell talks appointment of exclusive Australian distributor for Remplir - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Orthocell's CEO, Paul Anderson & Ticker News Interview - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Orthocell delivers outstanding results in Remplir nerve regeneration trial - Mr Paul Anderson Chief Executive Officer and Managing Director, Orthocell Ltd

Oventus Medical out to transform the sleep-disordered breathing market with new tech - John Cox , CEO, Oventus Medical Ltd

Oxurion: Developing Innovative Therapies for Diabetic Eye Disease - Patrik De Haes, CEO, Oxurion

Paion advancing its general anesthesia drug candidate - Wolfgang Soehngen, CEO, Paion

Executive Interview - Paion - Wolfgang Soehngen, CEO, Paion

Paradigm Biopharma – executive interview - Paul Rennie, CEO, co-founder and chairman, Paradigm Biopharmaceuticals Ltd

Paragon Care (ASX:PGC) Presentation, FNN Online Investor Event - Phil Nicholl, CEO, Paragon Care Ltd

Patrys CEO & MD, Dr James Campbell

Paxman AB (OM:PAX) Investor Presentation - Richard Paxman,CEO, Paxman AB (publ)

Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks- Gary Phillips, CEO, Pharmaxis Ltd

Gary Phillips, CEO of Australian biopharma company, Pharmaxis Ltd, discusses ensuring continuity of supply of its products - Gary Phillips, CEO, Pharmaxis Ltd

Realm Therapeutics plc - Equity Development Investor Forum - Alex Martin, CEO, Realm Therapeutics

Proteomics International focused on first commercial sales for PromarkerD in USA - Dr Richard Lipscombe, MD, Proteomics International Laboratories Ltd

Dr. Mariola Söhngen Chief Executive Officer and Executive Director, Proteome Sciences

Phylogica (ASX:PYC) talks strategy and platform direction - Stephanie Unwin, CEO, Phylogica Ltd

Lloyd Diamond Presents Pixium Vision - Lloyd Diamond CEO, Pixium Vision

Pixium Vision | Lloyd Diamond - President & CEO

Lloyd Diamond - Pixium Vision CEO, Pixium Vision

Pixium Vision - executive interview / Lloyd Diamond CEO, Pixium Vision

EnterNext welcomes Plant Advanced Technologies on Alternext in Paris - Jean-Paul Fèvre, Founder and CEO of Plant Advanced Technologies

PledPharma CEO, Nicklas Westerholm

Polarean Imaging receives "clear indication of belief in the company" from major shareholder - Dr. Christopher von Jako Chief Executive Officer, Polarean Imaging

Chris von Jako, chief executive of Polarean, about the company’s five pillar strategy to drive uptake of its life saving lung imaging technology. Chris von Jako, chief executive of Polarean, about the company’s five pillar strategy to drive uptake of it

Steve Harr, CEO of Sana Biotechnology

Probiodrug pursues modified abeta approach to tackle Alzheimer's- Dr. Konrad Glund, CEO, Probiodrug

ProMIS Neurosciences reckons it has the only assets to tackle - Eugene William , Promis Neurosciences Inc

Jonas Ekblom, CEO, Promore Pharma

Promore Pharma Interview | April 2023 - Jonas Ekblom, CEO, Promore Pharma

SELLAS Life Sciences Group - Licensed Asset Aims To Prolong Survival in Cancer Patients - Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group

Saniona President and CEO Rami Levin provides an overview of near-term milestones for key clinical programs - Rami Levin, CEO, Saniona

RLS Global - Naventus Life Science Summit - Karin Fischer, CEO, RLS Global

ReWalk Robotics Ltd RWLK CEO Larry Jasinski

RedHill Biopharma (NASDAQ: RDHL) Presenting the company - Gay Goldberg, CBO, Redhill Biopharma Ltd

Redx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz Pharma - Lisa Anson Chief Executive Officer, Redx Pharma

Redx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008 - Lisa Anson Chief Executive Officer, Redx Pharma

Redx Pharma begins testing lead drug in phase II trial for idiopathic pulmonary fibrosis - Lisa Anson Chief Executive Officer, Redx Pharma

RedX Pharma drug candidate pipeline underpins strong first half progress - Lisa Anson Chief Executive Officer, Redx Pharma

Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress - Lisa Anson Chief Executive Officer, Redx Pharma

Regeneus ASX:RGS May 2021 Business Update - Karolis Rosickas, CEO, Regeneus Ltd

Company update and season’s greetings from Regeneus Dec 2020 - Karolis Rosickas, CEO, Regeneus Ltd

ReNeuron / Michael Hunt, Chief Financial Officer, ReNeuron Group

ReNeuron Group's phase IIb stroke trial kicks off with first patient treated - Michael Hunt, Chief Financial Officer, ReNeuron Group

Michael Hunt CFO of ReNeuron Group (RENE) at SHARES Innovators and Investors Forum - Michael Hunt, Chief Financial Officer, ReNeuron Group

ReNeuron focus on new clinical trials - Michael Hunt, Chief Financial Officer, ReNeuron Group

Lots to look forward to' as ReNeuron gets go-ahead for phase IIb stroke trial - Michael Hunt, Chief Financial Officer, ReNeuron Group

Respiri Presentation - 2021 NWR Virtual Investor Conference - Marjan Mikel Chief Executive Officer, Respiri Ltd

Respiri - executive interview - Marjan Mikel Chief Executive Officer, Respiri Ltd

Respiri talks Access Telehealth acquisition and US growth - Marjan Mikel Chief Executive Officer, Respiri Ltd

Scancell Holdings "well-financed" and continuing to pursue deals - Professor Lindy Durrant (Chief Executive Officer, Chief Scientific Officer), Scancell Holdings

Scancell Holdings' present progression and pipeline plan now firm is fully funded for all programmes - Professor Lindy Durrant (Chief Executive Officer, Chief Scientific Officer), Scancell Holdings

Scancell Holdings PLC (AIM:SCLP) (OTC:SCNLF) - Lindy Durrant CEO - Professor Lindy Durrant (Chief Executive Officer, Chief Scientific Officer), Scancell Holdings

Scancell CEO hails "exciting" high response rate to melanoma treatment - Professor Lindy Durrant (Chief Executive Officer, Chief Scientific Officer), Scancell Holdings

Sensorion seeks partner for inner ear disorder drug - Nawal Ouzren, CEO, Sensorion

SenzaGen presentation - Peter Nählstedt President and CEO, SenzaGen

SenzaGen CEO Peter Nählstedt present the company - Peter Nählstedt President and CEO, SenzaGen

SenzaGen CEO Peter Nählstedt presents the company at Vator Securities Healthcare Innovation Summit - Peter Nählstedt President and CEO, SenzaGen

SenzaGen presentation - Peter Nählstedt President and CEO, SenzaGen

CEO Peter Nählstedt presents SenzaGen - Peter Nählstedt President and CEO, SenzaGen

CEO Pia Renaudin presents Senzime - Pia Renaudin, CEO, Senzime AB (publ)

Interview with Dr. Philip Toleikis, President & CEO of Sernova Corp. - Dr. Philip Toleikis, President & CEO of Sernova Corp.

Shield Therapeutics "ended 2022 in a very very productive state" - Greg Madison Chief Executive Officer, Shield Therapeutics P

Shield Therapeutics 'delivered an excellent first half' with Accrufer powering ahead in the US - Greg Madison Chief Executive Officer, Shield Therapeutics P

Shield Therapeutics talks extension of cash runway following US$10 million financing - Greg Madison Chief Executive Officer, Shield Therapeutics P

Shield Therapeutics "couldn't be more pleased" with Viatris collaboration - Greg Madison Chief Executive Officer, Shield Therapeutics P

Shield Therapeutics' present drive for US launch success of iron deficiency product Accrufer - Greg Madison Chief Executive Officer, Shield Therapeutics P

Sienna Cancer Diagnostics (ASX:SDX) talks IVD test sales - Matthew Hoskin, CEO, Sienna Cancer Diagnostics Ltd

Sienna Cancer Diagnostics (ASX:SDX) update - Matthew Hoskin, CEO, Sienna Cancer Diagnostics Ltd

SQI Diagnostics (TSXV:SQD) Can Multiplex a Blood Test: CEO - Andrew Morris DIRECTOR AND CHIEF EXECUTIVE OFFICER, SQI Diagnostics Inc

CEO Andrew Morris talks about the big steps SQI has taken in its corporate development - Andrew Morris DIRECTOR AND CHIEF EXECUTIVE OFFICER, SQI Diagnostics Inc

Silence Therapeutics - The GOLDen future of RNAi Research - Mark Rothera, President and CEO of Silence Therapeutics

Introducing Silence Therapeutics - Mark Rothera, President and CEO of Silence Therapeutics

SkinBio Therapeutics (SBTX) is a life science company - Stuart Ashman Chief Executive, Skinbiotherapeutics

SkinBioTherapeutics (SBTX) - Stuart Ashman, CEO

SkinBioTherapeutics will "continue to be flexible enough to adapt to opportunities" - Stuart Ashman Chief Executive, Skinbiotherapeutics

Skinbiotherapeutics get set for live data trial to target skin conditions including psoriasis - Stuart Ashman Chief Executive, Skinbiotherapeutics

Mike Timoney: Introduction to Smiles Inclusive - a new model for dental partnerships - Mike Timiney, CEO, Smiles Inclusive Ltd

Smiles Inclusive (ASX:SIL): Mike Timoney, Chief Executive Officer

Soligenix; An Introduction to Christopher J. Schaber - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Soligenix, Inc.'s interview with Dr. Christopher J. Schaber, Chairman, President, and CEO - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

"Treating Rare Diseases" – Soligenix, Inc.'s interview - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Soligenix Inc is a late-stage biopharmaceutical company - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Soligenix CEO Chris Schaber highlights the company's major milestones - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Chris Schaber, Soligenix Inc., talks about the collaborative efforts of the industry in response to COVID-19 - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases - Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

Christopher J. Schaber, PhD Chairman, President and Chief Executive Officer, Soligenix Inc

CEO Erik Kinnman presents Sprint Bioscience - Erik Kinnman, CEO, Sprint Bioscience

CEO Andrew Morris explains why SQI’s recently-announced product development agreement - Andrew Morris DIRECTOR AND CHIEF EXECUTIVE OFFICER, SQI Diagnostics Inc

David Marsh Chief Executive Officer, Surgical Innovations Group P

Synairgen looking beyond COVID in fight against respiratory illness - Richard Marsden Chief Executive Officer, Executive Director, Synairgen

John Bonfiglio, Ph.D., Chairman and CEO of TapImmune, Inc.

Targovax presentation at Redeye Fight Cancer - Erik Digman Wiklund, CEO, Targovax

Telix Pharmaceuticals Limited (ASX:TLX) - Christian Behrenbruch, CEO, Telix Pharmaceuticals Ltd

BUSINESS TALK YEARLY 2020 By Torn Pracharktam, CEO of Thai Optical Group Pcl

David Caumartin CEO Theraclion ‘’ How tisrupt Image guided Robotic platform with AI’’ - David Caumartin CEO at Theraclion

Interview Michel Finance, Director, Theradiag

Interview with Shawn Shirazi, CEO of Theralase Technologies

Shawn Shirazi, Chief Executive Officer , Theralase Technologies Inc.

Listing of Theranexus on Euronext Growth - Franck Mouthon and Mathieu Charvériat, founders of Theranexus

Tissue Regenix Group "has the opportunity to become a global commercial organisation" - Danny Lee, CEO, Tissue Regenix Group

Tissue Regenix Group looking to expand sales beyond the US - Danny Lee, CEO, Tissue Regenix Group

Tissue Regenix Group says "disciplined approach" paying off at half-year stage - Danny Lee, CEO, Tissue Regenix Group

David McNally, CEO | Titan Medical Inc.

Tristel (TSTL) - Paul Swinney, CEO

Stéphane Boissel, CEO, Txcell SATXCL:PAR

Universal Biosensors (ASX:UBI) John Sharman, CEO, Universal Biosensors Inc

Sébastien Peltier, CEO of Valbiotis

iroGates on positive EMA opinion of suPAR-guided Kineret treatment - Jakob Knudsen , CEO, ViroGates

Visioneering Technologies' growth strategies to tackle COVID-19 - Dr Stephen Snowdy, CEO, Visioneering Technologies Inc

Volpara Health Technologies with Proactive at the ASX Small and Mid-Cap Conference - Teri Thomas , CEO, Volpara Health Technologies Ltd

Interview with Xspray Pharma - Per Andersson, CEO at Xspray Pharma

Gerald Solensky Jr., Chairman and CEO of Zomedica Pharmaceuticals Corp.

Michael Doss CEO of Graphic Packaging recently invested $600 million in a new facility here in Kalamazoo

The Story of Beam Therapeutics | John Evans, CHIEF EXECUTIVE OFFICER, BEAM THERAPEUTICS INC

Belite Bio (Nasdaq: BLTE) Handling incurable ocular conditions | Dr Tom Lin, FOUNDER, CHAIRMAN, AND CHIEF EXECUTIVE OFFICER, BELITE BIO INC

Asher Bio's Ivana Djuretic in a Fireside Chat | CRAIG GIBBS, PHD, MBA, CHIEF EXECUTIVE OFFICER, ASHER BIOTHERAPEUTICS, INC

CEO of Aspect BioSystems Tamer Mohamed speaks at the LSI USA '22 Emerging Medtech Summit | Tamer Mohamed, PRESIDENT & CEO, ASPECT BIOSYSTEMS LTD

The Avellino Corneal Dystrophy test is available from Avellino Lab USA | Thomas Kim, PRESIDENT & CEO, AVELLINO LAB

AusBiotech with The Matter of Gene Patents | Lorraine Chiroiu, CHIEF EXECUTIVE OFFICER, AUSBIOTECH

ATA188: an EBV-specific T cell allogeneic treatment for MS progression | Pascal Touchon, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ATARA BIOTHERAPEUTICS INC

Advanced Health on revamping private healthcare in South Africa | Gerhard Van Emmenis, CHIEF EXECUTIVE OFFICER, ADVANCED HEALTH LIMITED

Results of a Pompe disease treatment trial are discussed by John Crowley | Bradley L. Campbell, PRESIDENT AND CHIEF EXECUTIVE OFFICER , AMICUS THERAPEUTICS, INC.

Gene and Cell Therapy Andelyn Biosciences CDMO | Wade Macedone, CHIEF EXECUTIVE OFFICER, ANDELYN BIOSCIENCES

Applied Pharmaceuticals and Voyageur Pharmaceuticals collaborate on carbon-based imaging medications | Andrew MacIsaac, CHIEF EXECUTIVE OFFICER, APPLIED PHARMACEUTICAL INNOVATION

Apollo Therapeutics: Converting cutting-edge research into possible treatments | Dr Richard Mason, CHIEF EXECUTIVE OFFICER, APOLLO THERAPEUTIC

Dr. Dan Bloomfield Discusses Abelacimab's Advantages | JOHN GLASSPOOL, CEO, ANTHOS THERAPEUTICS

Grindeks chairman of the board Juris Hmelnickis

Revolutionizing Healthcare Through Genetic Transparency and Choice|Anne Wojcicki, CEO, 23andme holding co.

Revolutionizing Genetic Research Through Consumer Empowerment and Participation|Anne Wojcicki, CEO, 23andme holding co.

Transforming Respiratory Diagnostics: 4D Medical's Innovative Healthcare Journey| Dr Andreas Fouras, CEO, 4dmedical ltd.

4D Medical Achieves Milestone: Generates First Clinical SAS Revenue and Explores International Expansion with Revolutionary Respiratory Imaging Technology| Dr Andreas Fouras, CEO, 4dmedical ltd.

Navigating the Challenging Landscape of NASH Therapeutics| Rohan Palekar, CEO, 89bio Inc.

CEO Alain Moussy Expounds on the Complex Journey of Masitinib Development in Interview| Alain Moussy, CEO, AB Science SA.

From Tinkering with Appliances to Transforming Clinical Trials|Ryan Jones,CEO,Florence Healthcare

Phase 2a Trial of CER-001 for Septic Patients and Future Biotech Meetings | Cyrille Tupin, CEO, Abionyx Pharma SA .

Navigating Biotech Leadership: Insights, Risks, and Personal Growth from an Industry Veteran | Marc de Garidel, CEO, Abivax SA.

Exploring Breakthroughs: Insights into Mitochondrial Disease Treatments and Clinical Trials | Ellen Wittmack Donnelly, CEO, Abliva AB.

Revolutionizing Drug Discovery with AI: Accelerating Medicine Development through Innovative Biologics| Sean McClain, CEO, Absci Corp.

Navigating the Intersection of AI and Biology: A Vision for Drug Discovery| Sean McClain, CEO, Absci Corp.

Exploring the Intersection of Entrepreneurship and Alzheimer's Research: A Female Leader's Journey|Andrea Pfeifer, CEO, AC Immune SA.

Advancing Therapeutic Solutions for Rare Diseases: Acer's Diverse Clinical Pipeline|Chris Schelling, CEO, Acer Therapeutics Inc.

Developing a Promising Smoking Cessation Drug with Favorable Safety Profile for a Large Market Opportunity| John Bencich, CEO, Achieve Life Sciences Inc.

Navigating the Success and Future Prospects of a Promising Smoking Cessation Asset| John Bencich, CEO, Achieve Life Sciences Inc.

Exploring Science Advocacy and Influential Leadership in Neurological Disorders| Dr. Ron Cohen, CEO, Acorda Therapeutics Inc.

Exploring Entrepreneurial Journeys and Industry Insights| Gilles Avenard , CEO, Acticor Biotech SA.

Exploring the Landscape of Biotech Innovations| Gilles Avenard , CEO, Acticor Biotech SA.

Cutting-Edge Cancer Therapies and Financial Strategies at the Biotech Showcase in San Francisco| Sadesh Seth , CEO, Actinium Pharmaceuticals Inc.

In-depth discussion on neuro therapeutics and strategic priorities for the next 18 months by Actinogen Medical Ltd CEO|Steven Gourlay , CEO, Actinogen Medical Ltd.

Developing Novel Therapy for Neurological Diseases Associated with Dysregulated Brain Cortisol|Steven Gourlay , CEO, Actinogen Medical Ltd.

Biotech CEO presents promising clinical trial results and upcoming milestones |Helen Tuvesson , CEO, Active Biotech AB

Biopharmaceutical CEO discusses promising Phase 3 trial results of a novel antibiotic for Clostridioides difficile Infections with potential market impact exceeding $1B |David P Luci , CEO, Acurx Pharmaceuticals Inc.

Exploring Biotech Advancements and Talent Growth in Washington |Chad Robbin , CEO, Adaptive Biotechnologies.

Pioneering Immune Medicine and Driving Collaborative Health Tech Solutions. |Chad Robbin , CEO, Adaptive Biotechnologies.

Addex Therapeutics' Advancements in Allosteric Modulation and Collaborative Ventures in CNS Pharmaceuticals |Tim DyerCo , CEO, Addex Therapeutics Ltd.

Navigating the Intersection of Politics and Medicine: Insights from a Health Ministry Veteran | Mr. Chi-Hsien Chan, CEO, Adimmune Corp .

Advancing Gene Therapy for Ocular Diseases: Lunar Phase 2 Trial Design and Clinical Significance | Laurent Fischer, CEO, Adverum Biotechnologies Inc .

A Revolutionary Paradigm for Understanding Human Existence| Pier Vincenzo Piazza, CEO, Aelis Farma SA.

Unity and Collaboration: A Holistic Approach to Healthcare |Ahmed Banderker, CEO, Afrocentric Investment Corporation.

Innovative Healthcare Solutions for Greater Accessibility and Affordability |Ahmed Banderker, CEO, Afrocentric Investment Corporation.

Exploring Latest Developments in Biotech Assets and Financial Outlook |Pier Vincenzo Piazza, CEO, Aelis Farma SA.

Biotech Analysts Unveil AI's Impact: Revolutionizing Drug Discovery for a Promising 2024|JEFFREY M. SOLOMON,President, TD Cowen

Innovative Pharmaceutical Company Accelerates Growth and Forges Strategic Partnerships |Hartley Atkinson, CEO, AFT Pharmaceuticals Ltd .

Journey of Success: Dr. Garo Armen's Inspiring Life and Impact on Science, Entrepreneurship, and Philanthropy |Hartley Atkinson, CEO, AFT Pharmaceuticals Ltd .

Navigating the IPO process, CEO discusses the critical role of his company in healthcare infrastructure and its resilience amidst challenges |Tom Leonard, CEO, Agiliti Inc .

Exploring Agios' Pioneering Approach at the Intersection of Cancer Metabolism and Genomics | Brian Goff, CEO,Agios Pharmaceuticals Inc .

Exploring Innovations, Ethical Ventures, and the Pursuit of Longevity with a Diverse Investor and Advocate | Jim Mellon, CEO, Agronomics Ltd .

Exploring the Future of Cellular Agriculture: Innovations, Implications, and Supermarket Shelves|Jim Mellon, CEO, Agronomics Ltd .

Overview of AIM ImmunoTech's Pancreatic Cancer Program with Promising Follow-On Data Release| Thomas Equels, CEO, AIM ImmunoTech Inc.

Building a Biotech Hub: Insights from an Entrepreneur's Perspective on Boston's Vibrant Ecosystem and the Importance of Physical Space for Team Collaboration|Rachelle Jacques, CEO, Akari Therapeutics PLC.

Navigating the Allergy Therapeutics landscape: Insights into Market Expansion and Financial Strength |Manuel Llobet, CEO, Allergy Therapeutics PLC.

Update on Alligator Bioscience's Clinical Trials and Pipeline Progress, Anticipating Positive Outcomes and Partnership Discussions |Søren Bregenholt, CEO, Alligator Bioscience AB.

Analyzing Allergy Therapeutics' Financial Performance and Promising Developments Amid Record Pre-R&D Operating Profit and Successful Biomarker Study |Manuel Llobet, CEO, Allergy Therapeutics PLC.

Unlocking the Secrets of Human Aging: The Role of Telomeres and Telomerase |Dr. Michael D. West , CEO, AgeX Therapeutics Inc .

Navigating Forward-Looking Statements and Risks in AIM ImmunoTech's Interview| Thomas Equels, CEO, AIM ImmunoTech Inc.

Akari Therapeutics' Innovative Approach to Treating Rare Hematopoietic Stem Cell Transplant Complications| Rachelle Jacques, CEO, Akari Therapeutics PLC.

Exploring Innovations in Cancer Immunotherapy|Søren Bregenholt, CEO, Alligator Bioscience AB.

Exploring Agios' Pioneering Approach at the Intersection of Cancer Metabolism and Genomics | David Schenkein, CEO,Agios Pharmaceuticals Inc .

CEO Discusses Strategic Vision for Environmental, Social, and Governance Initiatives|Gianfranco Nazzi, CEO, Almirall SA.

Navigating the landscape of medical cannabis opportunities and risks with insights from industry experts |Josh Fegan, CEO,Althea Group.

Alvotech's Integrated Approach and Expansive Pipeline Energize Pharmaceutical Markets Worldwide|Róbert Wessman, CEO, Alvotech SA.

Biotech CEO discusses advancements in Alzheimer's and psychiatric disorder treatments, highlighting promising clinical results and future prospects |Stephan Jackman, CEO, Alzamend Neuro Inc.

A NEW SOLUTION TO QUIT SMOKING|John Bencich,Chief Executive Officer,Achieve Life Sciences Inc

Analytical tools and techniques to reverse engineer and characterise the composition of reference products|Michael Kotsanis,CEO,Acrux Ltd

Cognitive functions include episodic and working memory attention problem solving and language|Dr Steven Gourlay,CEO,Actinogen Medical Ltd

Developing innovative solutions to debilitating diseases|Tim Oldham PhD,CEO,Adalta Ltd

Allosteric modulators for Human Health|TIM DYER,CEO,Addex Therapeutics Ltd

Developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products|Klaus Paulini,CEO,AEterna Zentaris Inc

Creating partnerships to change medicine|Charles Walker,CEO,Alchemia Ltd

Developing next generation peptide therapeutics for obesity and liver disease|Vipin K Garg,President,Altimmune Inc

Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis|Steve martin, CFO,AmpliPhi Biosciences Corp

Empower the body to fight disease|Anders Haegerstrand,Chief Executive Officer,Annexin Pharmaceuticals

Addressing global challenges with societally-beneficial solutions|Dr Geoffrey Cumming,DIRECTOR,Anteo Diagnostics Ltd

Treatment options for patients with rare disease are limited|Mark Diamond,CEO,Antisense Therapeutics Ltd

Broad Applicability Across the Hematology Spectrum|William Rice,CEO,Aptose Biosciences Inc

Precision medicine approach to drug development tailoring medical treatment to the individual genetic characteristics of patients|Thomas A Keuer,President,ARCA Biopharma Inc

Asit Biotech Biopharmaceutical company specialized in allergies|Michel Baijo,CEO,Asit Biotech

Biomarker testing could dramatically improve patient health outcomes|Francois Desjardins,Vice President,Bellus Health

Benitec Biopharma Inc is a clinicalstage biotechnology company advancement of novel genetic medicines|Dr. Jerel Banks,Director,Benitec Biopharma Ltd

Building Bridges in Medical Dermatology|Steven M. Bosacki,Chief Executive Officer,Biopharmx Corp

A provider of new and effective solutions within wound care cancer therapies and other immune related disease areas|Svein WF Lien, CEO,Biotec Pharmacon

An impressive portfolio of compounds with activity against a broad range of viral diseases|Dr Michelle Miller, Managing Director,Biotron Ltd

Treatment Decisions With Greater Confidence|Anders Rylander,CEO,Biovica International

Redefining Medicine for a Healthier Tomorrow|Sam Watson,CEO,Bioxyne Ltd

Innovators and commercial leaders in dermatology|Matt Callahan,Executive Director,Botanix Pharmaceuticals Ltd

BPH Energy Ltd Entitlement Issue Prospectus and Target Market Determination|Mr David Breeze,Managing Director,BPH Energy Ltd

C4XD aims to efficiently deliver world leading immunoinflammatory medicines|Clive Dix,CEO,C4X Discovery Holdings

Discover develop and deliver innovative therapies for the treatment of advanced solid tumors and other major diseases|David J. Mazzo,President,Caladrius Biosciences Inc

The 1.7Moz Warrawoona Gold Project located in the Pilbara Goldfield of Western Australia|David Reeves,Managing Director,Calidus Resources Ltd

Our goal is to treat cancer as well as inflammatory and autoimmune diseases|Göran Forsberg,CEO,Cantargia

Ceapro's patented process technologies include Pressurized Gas eXpanded technology|Gilles Gagnon,President,Ceapro Inc

Focus on Drug discovery research development and manufacturing of complex biological substances,Geert Kersten ,Ceo,CEL-SCI Corp

Cellmid develops innovative therapies and diagnostics for cancer inflammation and heart attack|MARIA HALASZ,CEO,Cellmid Ltd

Contribute to the development of innovative therapies for patients without existing or effective treatment|Cyrille Tupin,CEO,Cerenis Therapeutics Holding

Accelerating Drug Development Through Superior Innovative Solutions|Ronnie Morris, MD,Champions Oncology Inc

Biopharmaceutical company focused on the development and commercialization of firstinclass critical care products|Myron Holubiak,CEO,Citius Pharmaceuticals

Developing A New Class of Immunotherapies|Julie M Clifford,Vice President,Cleveland Biolabs Inc

SUPERIOR SAFETY PROFILE WITH MINIMAL SIDE EFFECTS|JOHN CAVAN,CEO,ContraVir Pharmaceuticals Inc

Based on proprietary heparin technology Corline Biomedical develops Renaparin to improve kidney transplantation|Henrik Nittmar, CEO,Corline Biomedical

We relentlessly pursue therapeutic options to reduce and treat infectious and inflammatory disease|Joe Todisco,Chief Executive Officer,CorMedix Inc

Redmoor contains valuable amounts of tin tungsten and copper all are metals needed for our future|Peter Wale,Director,Cornwall Resources Inc

Crescita is a growthoriented innovationdriven Canadian commercial dermatology company with inhouse R&D|Daniel N Chicoine,Chairman,Crescita Therapeutics Inc

Creso Pharma Switzerland: CBD related research development and commercialization|Boaz Wachtel,Chairman,Creso Pharma Ltd

IMPROVED PATIENT OUTCOME|Shane Ray, Chief Marketing Officer,Curasan

Harnessing the cell cycle to treat cancer and other serious diseases|Spiro Rombotis,President,Cyclacel Pharmaceuticals Inc

Cynata is focussed on the development and commercialisation of a proprietary|Dr Kilian Kelly,Chief Executive Officer,Cynata Therapeutics Ltd

We are driven by the pursuit of safe and effective medical devices that improve the health and well-being of people|Marc Hedrick,President,Cytori Therapeutics Inc

Transformative Therapies for Autoimmune Diseases|Carl Magnus Hogerkorp,CEO,Cyxone

Our initial focus areas include contraception fertility and sexual and vaginal health|SABRINA MARTUCCI JOHNSON,President,Dare Bioscience Inc

Diamyd Medical develops therapies for type 1 diabetes|Anders EssenMoller,Chairman,Diamyd Medical

We believe the key to treating neurodegenerative disease is to intervene early|David Kalergis,CEO,Diffusion Pharmaceuticals Inc

Protect your future with geneType risk assessment|Simon Morriss,CEO,Genetic Technologies Ltd

Healthcare Sector Veteran Britt Meelby Jensen Joins KRING Speedbooting as Investor, Bringing Extensive Expertise and Network in Biotech, Medtech, and Diagnostics |Britt Meelby Jensen, CEO,Ambu A/S.

From humble beginnings working in a candy store to co-founding a successful pharmaceutical company, Chintu's journey exemplifies perseverance, family support, and entrepreneurial spirit |Chintu Patel, CEO, Amneal Pharmaceuticals Inc.

Innovation, Growth, and Sustainability: A Conversation on Hearing Care |Enrico Vita , CEO, Amplifon Spa .

Addressing the Impact of ACI: Innovating Therapeutic Solutions for Cannabinoid Intoxication |Simon Allen, CEO, Anebulo Pharmaceuticals Inc.

New Pharma Services Division Secures $1.2M Follow-On Contract for Innovative Cancer Patient Trial Assessment Approach |Andrew Newland, CEO, Angle PLC.

Exploring the Potential of a Revolutionary Cancer Vaccine | Amit Kumar, CEO, Anixa Biosciences Inc .

Advancements in Neurodegenerative Disease Treatment Research: Clinical Trials Update| Dr. Maria Maccecchini, CEO, Annovis Bio Inc.

Revolutionizing Cancer Screening: A Breakthrough in Liquid Biopsy Technology Unveiled| Chris Yu, CEO, AnPac Bio-Medical Science Co Ltd.

Navigating Ambu's Revival: Britt Meelby Jensen Shares Insights on Strategic Execution and Capital Optimization in the Life Science Industry |Britt Meelby Jensen, CEO,Ambu A/S.

Revolutionizing Worker Safety and Efficiency Through Smart Wearables: An Innovative Partnership |Neil Salmon, CEO, Anpario PLC.

Proprietary Nano Polymer Technology Poised to Revolutionize Clean Energy and Life Sciences Sectors, Targeting First Revenues|David Radford, CEO, Anteotech Ltd.

Next Target for Antibe Therapeutics' Proprietary Hydrogen Sulfide Platform: Inflammatory Bowel Disease (IBD)|Dan Legault, CEO, Antibe Therapeutics Inc.

Navigating Innovation and Customer Care in the Hearing Care Sector|Enrico Vita , CEO, Amplifon Spa .

New development partnership aims to revolutionize breast cancer diagnosis|Andrew Newland, CEO, Angle PLC.

Revolutionizing Neurodegenerative Disease Treatment| Dr. Maria Maccecchini, CEO, Annovis Bio Inc.

We are Advancing Immunology Solutions for a Better Future|Thomas K Equels, Chief Executive Officer,Hemispherx BioPharma

Develop disease modifying therapies to stop or reverse the progression of neurodegenerative diseases|ANTTI VUOLANTO,Chief Executive Officer,Herantis Pharma Oyj

we are focused on discovering developing and commercializing novel gene and cell therapies and vaccines|Jon Lieber, Chief Financial Officer,Histogenics Corp

Our naturally safe ingredients deliver pure nutritional performance and clinically-proven health benefits|Dr. Bomi Framroze,Chief Scientific Officer,Hofseth Biocare

Pharmaceutical solutions at every stage|Paul McDonald,Chief Executive Officer,

Venturing down unexplored paths|Carlos de sousa,CEO,Immunicum

Computing the future of medicine|Alan Whitmore,Chief Scientific Officer,E Therapeutics

Develop and launch solutions for challenges facing industries|Sean Smith,CEO,Eden Research

The science that protects life| Claus Egstrand,CEO,Enzymatica

Leading the development of sulforaphane based medicines|Dr Huw Jones, Executive Director,

Innovative vaccines for a healthier world|Bent U Frandsen, Chief Executive Officer,ExpreS2ion Biotech Holding

Improving sight in patients with severe vision loss|Brian M Strem,CEO,EyeGate Pharmaceuticals Inc

Developing and commercialising advanced wound care therapies|Christian Behrenbruch,CEO,Factor Therapeutics Ltd

Developing a portfolio of innovative products|James Barder,Chief Executive,Futura Medical

Focused on developing and commercializing proprietary molecular diagnostic tests for early detection of cancer|James Howard,CEO,genenews ltd

Accelerating Drug Discovery Through AI and Machine Learning|Martin Brenner,CEO,Ibio Inc

Our validated technology platform can produce orally active polyclonal antibodies|Steven Lydeamore,Chief Executive Officer,Immuron Ltd

Bringing Effective New Treatments And Options To Patients Who Need Them|Leslie Chong, CEO,Imugene Ltd

Unlocking the therapeutic potential of rare cannabinoids|Eric A. Adams,CEO,InMed Pharmaceuticals Inc

Development of a new generation of immune response modifier|Simon Wilkinson,CEO,Innate Immunotherapeutics Ltd

Precision medicine solutions for healthcare institutions|EMMANUELLE DEPONGE,CEO,Integragen

Develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology|Auwal Odidi,CEO,intellipharmaceutics international inc

A new generation of vaccines within animal health|Jonas Sohlman,CEO,Intervacc

Next-generation PDT that is more effective and overcomes the many shortcomings|Mr Thian Chew,CEO,Invion Ltd

we are focused on redefining the treatment of spinal cord injury|Richard Toselli,MD,InVivo Therapeutics Holdings Corp

Building the Premier Mitochondrial Medicine Company|Magnus Hansson,CMO,NeuroVive Pharmaceutical

We aim to be one of Indias most trusted pharmaceutical company|Glenn Smith,Managing Director,Novita Healthcare

"Stories of the Exchange" features CEO of Antibiotice Iași as Guest on TV |Ioan Nani, CEO, Antibiotice Iași.

Insightful interview with a biotech CEO discussing the company's focus on antisense therapies and the potential of their lead asset in treating Duchenne Muscular Dystrophy |James Garner, CEO,Antisense Therapeutics Ltd

Revolutionizing Therapy Adherence: The Single Pill Concept's Impact on Patient Well-being and Healthcare Costs |Karlheinz Gast, CEO, Apontis Pharma.

CEO of Aptamer Group PLC discusses anticipation of higher revenues in the second half following the release of interim results |Dr Arron Tolley, CEO, Aptamer Group PLC.

Insights from Aptos Biosciences CEO on Drug Development and Healthcare Systems at Blum Burton Conference | William Rice, CEO, Aptose Biosciences Inc .

Innovative Drug Delivery System for Patients with Swallowing Difficulties: Aquestive Therapeutics' Approach and Medications in Development | Daniel Barber, CEO, Aquestive Therapeutics Inc.

Pioneering Virology Company Aims to Develop Functional Cure for Hepatitis B and Treatments for Coronavirus Infections | William H. Collier, CEO, Arbutus Biopharma Corp.

Exploring the Evolution of Biotechnology: A Journey into RNA Medicines and Scientific Innovation |Joseph E. Payne, CEO, Arcturus Therapeutics Holdings Inc.

Significant Developments and Growth in Arecor Therapeutics' Operations Highlighted in Year-End Trading Update | Sarah Howell , CEO, Arecor Therapeutics PLC .

Revolutionizing Brain Injury Treatment: Breakthrough Trials Signal Collaborative Potential with Pharma Giants |Dr Liz Dallimore , CEO, Argenica Therapeutics Ltd.

Insights into AORA Biosurgery's innovative soft tissue reconstruction products, growth trajectory, and clinical trials |Brian Ward, CEO, Aroa Biosurgery Ltd .

Advanced cancer therapy shows promising results in licensing agreement announcement |Michael Baker, CEO, Arovella Therapeutics Ltd.

Innovative neuroprotective therapy ARG-007 shows promise in reducing brain cell death post-stroke, poised for phase one clinical trial |Dr Liz Dallimore , CEO, Argenica Therapeutics Ltd.

Empowering Women Leaders: Insights from AlbionVC's Conversation Series with Dr. Sarah Howell | Sarah Howell , CEO, Arecor Therapeutics PLC .

Revolutionizing Therapeutics: Advancements in RNA Medicines|Joseph E. Payne, CEO, Arcturus Therapeutics Holdings Inc.

The Company develops and manufactures liquids gels and creams for topical pain|Jesse Ledger,CEO,Nuvo Pharmaceuticals Inc

Discovering and developing products for patients with cancer|Dr. Steven Fruchtman,Ceo,Onconova Therapeutics Inc

Designed to Arm the Immune System to Fight Cancer|Dr. Robert Arch, President,OncoSec Medical Inc

Developing Treatments to Combat Resistant Infectious Diseases|Alan Dunton,MD,Oragenics Inc

NOVEL SOLUTIONS TO REGENERATE MOBILITY|Mr Paul Anderson,Chief Executive Officer,Orthocell Ltd

Develop and commercialise products that are better safer and easier to take|Marcelo Bravo,Chief Executive Officer,Oxford Pharmascience Group

IDENTIFYING UNDERUTILISED MOLECULES|PAUL RENNIE,MANAGING DIRECTOR,Paradigm Biopharmaceuticals Ltd

A revolutionary antibody approach for fighting cancer|James Campbell,Managing Director,Patrys Ltd

Treatment of cancer in dogs and neurodegenerative diseases in humans.|Dr Michael Thurn,Chief Executive Officer,PharmAust Ltd

Developing personalised medicine approaches to cancer|Steven Yatomi-Clarke,CEO,Prescient Therapeutics Ltd

Innovative Protein Folding Predictions|Eugene Williams,Chairman,Promis Neurosciences Inc

Pioneering medical technology company operating at the forefront of predictive diagnostics and bioanalytical services|Dr Richard Lipscombe,MD,Proteomics International Laboratories Ltd

Committed to advancing transformative therapies for people with cancer and rare diseases|MICHAEL SOLOMON,Director,Proteon Pharmaceuticals

Global biotechnology company with a dedicated mission to be at the heart of cancer care|Dr Daniel Tillett,Chief Executive Officer,Race Oncology Ltd

An Emerging Global Leader in the New Generation of Anti-Infective Therapies|James Graham,Managing Director,Recce Ltd

A paradigm shift in cellularbased therapy for regenerative medicine|Karolis Rosickas,Chief Executive Officer,Regeneus

Relief Therapeutics is a Swiss commercial stage biopharmaceutical company,Raghuram,Chairman,Relief Therapeutics

Australia's No.1 rental property website|Greg Bader,Chief Executive Officer,Rent.com.au Ltd

Rhinomed continues to invest in furthering our knowledge of the role the nose|MICHAEL JOHNSON,MANAGING DIRECTOR,Rhinomed Ltd

The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer|Robert Wassman, MD,Rosetta Genomics Ltd

Developing next generation kinase inhibitors for autoimmune disease & cancer|Tim Mitchell, CEO, Sareum Holdings plc

Pioneering prediction and prevention in dermatology|Pia Renaudin, CEO,SciBase Holdings

Sernova is a regenerative medicine therapeutics company|Dr. Philip M. Toleikis,CTO,Sernova Corp

committed to developing next-generation precision diagnostics and exosome solutions|Dr Gregory Rice,Chief Scientific Officer,Sienna Cancer Diagnostics Ltd

Sirona Biochem is a cosmetic ingredient and drug discovery firm with a proprietary technology|Géraldine Deliencourt-Godefro,CSO,Sirona Biochem Corp

SkinBioTherapeutics is targeting five specific skin healthcare sectors|Stuart Ashman,Chief Executive,Skinbiotherapeutics

Rising to the challenges of rare disease treatment|Christopher J. Schaber,Chairman,Soligenix Inc

AI-powered software for personalized screening and early detection of breast cancer|Teri Thomas,Chief Executive Officer,Volpara Health Technologies Ltd

Advancing Innovative Immune-Oncology Technologies|Jeffrey F. Eisenberg,Chief Executive Officer,Xenetic Biosciences Inc

PROVIDES BREAKTHROUGH ONCOLOGICAL DRUG CANDIDATES|JOHAN EMILSSON, Chief Executive Officer,Sprint Bioscience

Breakthrough Science for Severe Viral Lung Infections|Richard Marsden,Chief Executive Officer,Synairgen

Company will focus on the continued development and commercialization of T cell therapies|Peter L. Hoang,CEO,TapImmune Inc

A TOTAL SOLUTION FROM EXTRACTION TO DETECTION|Dr. Chang, Chairman,TBG Diagnostics Ltd

Developing new treatment options for cancer patients in indications with the greatest medical need|Bill Welch, CEO, Trovagene Inc

Develops cellbased immuno-therapies for the treatment of severe chronic inflammatory diseases|Stephane Boissel, CEO,Txcell

Vaccinogen Turning Cancer On Itself Through OncoVAX Immunotherapy|Michael G Hanna,CEO,Vaccinogen Inc

Accelerating biomedical innovation by connecting science finance and commerce|Dr Suzanne Dilly,Chief Executive Officer,ValiRx

A research and development company and license its current and future technologies|Mr Maurie Stang,Non Executive Deputy Chairman,Vectus Biosystems Ltd

Pushing RNA Interference Beyond Liver Diseases and into Diverse Therapeutic Areas |Christopher Richard Anzalone, CEO, Arrowhead Pharmaceuticals Inc.

Biotech Company Sees Strong Growth Amid Focus on Sustainability and Circular Economy |Gabriella Colucci, CEO, Arterra Bioscience S P A.

Challenges and Disparities in New Zealand's Aged Care System Prompt Concerns Over Future Accessibility and Quality of Care|Jeremy Nicoll, CEO, Arvida Group Ltd.

Discussion on Sparkle Study Enrollment, Endpoints, FDA Designation, and Market Potential for Novel Drug|Magnus Corfitzen, CEO, Ascelia Pharma AB.

Revolutionizing Surgical Technology: A CEO's Perspective on Advancements and Challenges in the Medtech Industry|Anthony Fernando, CEO, Asensus Surgical Inc .

Navigating Aspen Pharmacare's Performance Amidst COVID-19 Challenges and Vaccine Manufacturing Optimism|Stephen Saad, CEO, Aspen Pharmacare Holdings Ltd.

Advancing Women's Health through Early Detection: A Conversation with the CEO of Aspir Women's Health| Nicole Sandford, CEO, Aspira Women's Health Inc.

Advancements and Opportunities in Mental Health Treatment| Florian Brand , CEO, ATAI Life Sciences NV.

Navigating the Future of Surgical Innovation: Insights on Robotics, Digital Surgery, and Market Dynamics|Anthony Fernando, CEO, Asensus Surgical Inc .

An Entrepreneur's Journey of Strategy Pivots and Perseverance|Stephen Saad, CEO, Aspen Pharmacare Holdings Ltd.

Updates on OvaSuite®, OvaWatchSM, and EndoCheckTM Discussed in Fireside Chat with CEO| Nicole Sandford, CEO, Aspira Women's Health Inc.

For-Profit Approach in Psychedelic Medicine| Florian Brand , CEO, ATAI Life Sciences NV.

Strategies and Perspectives from an Experienced Industry Leader| Sharon Vitti , CEO, ATI Physical Therapy Inc.

Revolutionizing Breast Cancer Treatment: Innovative Drug Trials and Collaborations Target Aggressive Forms of the Disease |Dr. Quay , CEO, Atossa Therapeutics Inc.

Unlocking the Potential of Ancient Enzymes: A Dive into Cutting-edge Therapeutics Development | Sanjay Shukla , CEO, aTyr Pharma Inc.

Optimizing Accuracy in Medical Transcription Through Dual AI Model Integration| Manny Krakaris , CEO, Augmedix Inc.

Breakthrough Breast Cancer Therapy Insights: CEO Discusses Recent Study Results and Pipeline Developments |Dr. Quay , CEO, Atossa Therapeutics Inc.

Driving Access and Equity: A CEO's Vision for Affordable Physical Therapy Care and Female Leadership in Healthcare| Sharon Vitti , CEO, ATI Physical Therapy Inc.

Innovative Medical Device Company Explores Global Market at ASX Small and Mid-Cap Conference | John Kelly , CEO, Atomo Diagnostics Ltd .

Insights into Listing on ASX Amidst COVID-19 and Tips for a Successful IPO | John Kelly , CEO, Atomo Diagnostics Ltd .

Augmedix Aims to 'Re-Humanize Healthcare' Amid Increased Demand for Remote Medical Documentation Services | Manny Krakaris, CEO, Augmedix Inc.

Strategic Growth and Innovations Propel Cannabis Industry Success | Miguel Martin, CEO, Aurora Cannabis Inc.

Avadel's Innovations and Future Plans in Healthcare | Gregory J. Divis, CEO, Avadel Pharmaceuticals PLC

Navigating the cannabis industry's evolution and Avant Brands' strategic growth insights from CEO Norton| Gregory J. Divis, CEO, Avant Brands Inc.

Advancing Cannabinoid Research and Market Expansion| Aras Azadian, CEO, Avicanna Inc.

Pioneering Japanese CEO's Vision for Personal Health and Preventative Medicine | Kazuo Nakamura, CEO, CMIC Holdings Co Ltd.

Insights from Industry Leaders on Market Growth, Medical Focus, and Global Expansion Strategies | Miguel Martin, CEO, Aurora Cannabis Inc.

Addressing Structural Racism in Healthcare through Innovative Technology Solutions | Andrew Toy, CEO, Clover Health Investments Corp.

Clean Well Announces Share Buyback Program Amid Strong Financial Performance and Promising Pipeline Prospects | Dr Philippe Wolgen, CEO, Clinuvel Pharmaceuticals Ltd.

Kyle Detwiler brings extensive investment and leadership experience to Clever Leaves | Kyle Detwiler, CEO, Clever Leaves Holdings Inc.

Partnership with Shoppers Drug Mart to Enhance Medical Cannabis Access and Patient Care| Aras Azadian, CEO, Avicanna Inc.

Breakthrough MS Treatment Shows Sustained Improvement in Vision and Cognition Over 35 Months |Rob Etherington, CEO, Clene Inc.

Company's dual focus in Pharma and Cosmetics, highlighting efficient operations and optimism amidst market volatility | Dr Philippe Wolgen, CEO, Clinuvel Pharmaceuticals Ltd.

Transforming Healthcare: Innovating Incentives for Better Outcomes | Andrew Toy, CEO, Clover Health Investments Corp.

Upholding Innovation and Adaptability: CMIC's Enduring Creed | Kazuo Nakamura, CEO, CMIC Holdings Co Ltd.

Advancing Neurosurgical Procedures with Innovative MRI-Compatible Technology |Joseph M. Burnett, CEO, ClearPoint Neuro Inc.

Insights from Board Interview: Clarity's Founders, Healthcare, and Background |Dr Alan Taylor , Executive Chairma, Clarity Pharmaceuticals Ltd.

CEO discusses expansion of cancer biomarker technology research program and future commercialization plans with University of York collaboration | Allan Syms,CEO, Cizzle Biotechnology Holdings PLC.

Unveiling the Future: Cipla's Vision for Expanding Market Reach, Innovating with Semaglutide, and Navigating Regulatory Challenges | Umang Vohra ,CEO, Cipla Ltd.

From Molecular Biology to Biotech Entrepreneurship: Pioneering Antimicrobial Therapies and Novel Drug Development in Infectious Disease | Jeffrey Stei ,CEO, Cidara Therapeutics Inc.

Explores Pharmaceutical Industry's Antifungal Focus and Financing Landscape | Robert Fried ,CEO, Chromadex Corp.

CEO discusses sustainability and microbial technology's role in shaping a more eco-friendly food system | Mauricio Graber,CEO, Chr Hansen Holding A/S .

Radiopharmaceutical Innovations in Cancer Diagnosis |Dr Alan Taylor , Executive Chairma, Clarity Pharmaceuticals Ltd.

Cipla's Umang Vohra Highlights R&D Centre's Role in Product Innovation | Umang Vohra ,CEO, Cipla Ltd.

Jeff Stein Discusses Cidara Therapeutics' Mission in Antifungal Drug Development and Financing Strategies | Jeffrey Stei ,CEO, Cidara Therapeutics Inc.

Exploring the Transition from Hollywood to Anti-Aging: Insights from a Former Columbia Pictures Executive Turned Nutraceutical CEO | Robert Fried ,CEO, Chromadex Corp.

A Danish biotech firm, focusing on sustainable solutions through microbial technology across various industries| Mauricio Graber,CEO, Chr Hansen Holding A/S .

Chiome Bioscience leverages cutting-edge antibody technology for drug discovery and development| Shigeru Kobayashi,CEO, Chiome Bioscience Inc.

Advancing Precision Therapies for Kidney Diseases: Chinook's Pipeline and Clinical Progress Overview | Eric Dobmeier, CEO, Chinook Therapeutics Inc.

Jennifer Chow discusses promising results of cltx C therapy, signaling future trials and regulatory milestones in cancer treatment | Jennifer Chow, CEO,Chimeric Therapeutics Ltd.

Response to UK Disposable Vaping Ban | Callum Sommerton, CEO, Chill Brands Group PLC.

Global solidarity on World AIDS Day calls for increased funding |Richard Eberly, CEO, Chembio Diagnostics Inc.

Combining Medical Credibility with Approachable Counseling |Jacek Jakub Rozwadowski, President ,Centrum Medyczne Enel Med.

CEO discusses UK supermarket deal and revenue growth, highlighting shift to nicotine-free vape products and expansion plans for 2024 | Callum Sommerton, CEO, Chill Brands Group PLC.

The transformative potential of cell therapy for cancer treatment and highlights recent clinical advancements and team expertise | Jennifer Chow, CEO, Chimeric Therapeutics Ltd.

CEO elaborates on global efforts to enhance early diagnosis of rare hereditary diseases and metabolomics approaches to address diverse patient populations | Dr. Arndt Rolfs, CEO, Centogene NV.

CEO traces path from undergrad cancer biology interest to oncology biotech leadership | Filippo Petti, CEO, Celyad Oncology SA.

A Dive into the Transformative Potential of Stem Cells in Enhancing Health and Longevity, as Explored in an In-Depth Discussion| Robert Hariri, M.D., Ph.D., CEO, Celularity Inc.

Positive Quarterly Results and Long-Term Goals | Dr Maciej Wieczorek, CEO,Celon Pharma SA.

Insights from a CEO on Educating Physicians and Recognizing Diagnostic Challenges | Dr. Arndt Rolfs, CEO, Centogene NV.

Novel Cell Therapy Approaches for Oncology Highlight Manufacturing and Commercialization Strategies at Cell | Filippo Petti, CEO, Celyad Oncology SA.

AI Integration and SPAC Merger: Cellularity CEO Discusses Advances in Cancer Treatment and Lessons from the Pandemic| Robert Hariri, M.D., Ph.D., CEO, Celularity Inc.

Innovative Pharmaceuticals: Progress and Prospects Revealed by Industry Leader| Dr Maciej Wieczorek, CEO,Celon Pharma SA.

Biotech Innovator Advocates for Collaborative Healthcare Approach | André Choulika, CEO,Cellectis SA.

Exploring Cellectar's Cutting-Edge Cancer Treatment and Biotech Challenges | James V Caruso, CEO,Cellectar Biosciences Inc.

Unlocking UK's Cannabis Potential: Celadon Pharmaceuticals' Path| James Short , CEO,Celadon Pharmaceuticals PLC.

Harnessing the Power of the Placenta: A Journey in Cellular Medicine Innovation and Preservation of Human Performance| Robert Hariri, M.D., Ph.D., CEO, Celularity Inc.

Advancing Alzheimer's Treatment: CEO Discusses Promising Phase 2 Data and Multi-dimensional Drug Approach | Remi Barbier, CEO, Cassava Sciences Inc.

Carmat's clinical developments, production capabilities, and financial situation | Stéphane Piat, CEO, Carmat SA.

Alzheimer's Disease Solutions | Remi Barbier, CEO, Cassava Sciences Inc.

Unique Cell Therapy Platform's Promise| Steven Kelly, CEO,Carisma Therapeutics Inc.

A pioneering figure in CRISPR technology, recognized for her outstanding contributions to science and healthcare, shaping the future of biotechnology | Rachel Haurwitz, CEO, Caribou Biosciences Inc.

Analyzing the Biotechnology Market: Insights into Trends, Challenges, and Future Outlook | André Choulika, CEO,Cellectis SA.

Insights into French Biotech: Challenges and Opportunities in Healthcare Innovation Explored by Industry Expert | André Choulika, CEO,Cellectis SA.

Advancing Cardiac Solutions: A Conversation on Carmat's Breakthroughs and Future Goals | Stéphane Piat, CEO, Carmat SA.

Advancements in Biocompatible Artificial Heart Technology and Future Prospects | Stéphane Piat, CEO, Carmat SA.

Expert Discusses Skin Cancer Screenings and Free Diagnostic Testing Opportunities on Sonoran Living |Derek J Maetzold, CEO, Castle Biosciences Inc.

Optimizing CareRx's Future: CEO Puneet Khanna Shares Strategic Vision and Financial Insights|Puneet Khanna, CEO, CareRx Corp.

Expanding Presence in Ontario's Long-Term Care Sector|David Murphy, CEO, CareRx Corp.

Unlocking the Potential of Generative AI in Healthcare: Expert Perspectives and Innovations | A. Hadi Chaudhry, CEO, CareCloud Inc.

Advancements in Genetic Testing and Tumor Profiling for Uveal Melanoma Management |Derek J Maetzold, CEO, Castle Biosciences Inc.

Embracing Change: A CEO's Journey through Innovation and Growth| A. Hadi Chaudhry, CEO, CareCloud Inc.

FDA Grants Orphan Drug Designation to Cardiol Therapeutics' Lead Candidate for Recurrent Pericarditis| David Elsley, CEO, Cardiol Therapeutics Inc.

Strategies for Recruiting and Retaining Top Talent in Today's Competitive Landscape | A. Hadi Chaudhry, CEO, CareCloud Inc.

Promising Study Reveals Cardiol Therapeutics' Subcutaneous Cannabidiol's Potential in Heart Failure Treatment| David Elsley, CEO, Cardiol Therapeutics Inc.

Navigating Career Pathways: Insights from a Neuroscientist Turned Oncology CEO| Mark Erlander, CEO, Cardiff Oncology Inc.

Canopy Growth CEO Discusses Market Expansion and Profitability Outlook| David Klein, CEO, Canopy Growth Corp.

Germany's Move to Partially Legalize Cannabis Drives Significant Surge in Stock| David Klein, CEO, Canopy Growth Corp.

Cardio Therapeutics aims to revolutionize cardiovascular medicine through groundbreaking research and pivotal clinical trials | David Elsley, CEO, Cardiol Therapeutics Inc.

Unlocking the Potential of K-RAS Mutations in Cancer Therapy| Mark Erlander, CEO, Cardiff Oncology Inc.

Cano Health's explosive growth and innovative approach to value-based primary care for Latino seniors |Mark Kent, CEO,Cano Health Inc.

Unlocking the Potential of Medicinal Cannabis: Innovations in Therapeutic Solutions | Mark Lucas, CEO, Cannasouth Ltd.

Positive Financial Results Signal Growth Potential| David Klein, CEO, Canopy Growth Corp.

Cannasouth emphasizes science-led innovation in medicinal cannabis development | Mark Lucas, CEO, Cannasouth Ltd.

Crafting Success in Healthcare: CEO Insights on Industry Trends and Strategies | A. Hadi Chaudhry, CEO, CareCloud Inc.

Biotech Company CEO Discusses CAM2038 on Stockholm Stock Exchange Listing Day | Fredrik Tiberg, CEO, Camurus AB.

Revolutionizing Healthcare Staffing: Harnessing Technology for Efficiency and Success | Cary Grace - President & Chief Executive Officer of AMN HEALTHCARE SERVICES INC

Jerry Shelton & Mark Sawicki of Cryoport: Keynote at Advanced Therapies Congress 2019 | Jerry Shelton - CEO of Cryoport, Inc.

Cryoport CEO Jerrell Shelton Discusses Stock Rally on CNBC's Power Lunch | Jerry Shelton - CEO of Cryoport, Inc.

CEORoadshow: Jerrell Shelton, President & CEO of Cryoport | Jerry Shelton - CEO of Cryoport, Inc.

Empowering Cancer Patients: Cartherix's Innovative Approach to Solid Cancer Treatment|Professor Alan Trounson,CEO,Cartherics

Inside Cartherics: A Comprehensive 5-Minute Investor Overview|Professor Alan Trounson ,CEO,CARTHERICS

Cartherics is now developing NK cells with dual CARs that provide a grab and punch killing mechanism|Professor Alan Trounson,CEO,Cartherics

Tinkering with Appliances to Transforming Clinical Trials|Ryan Jones,CEO,Florence Healthcare

Matthias points out that while the problem is complex and global, starting with small, tangible actions such as a "green pass" for companies to limit their carbon emissions can make a difference|Matthias Steger,CEO,Endogena Therapeutics

Transitioning from IV infusions to subcutaneous injections can indeed make a significant difference in patient comfort and convenience|Lynn Hartung,President,Qprotyn

At the Canadian Investment Conference to discuss the technology behind Theralase's Laser Treatment Therapy, the users, and their market|Roger White,CEO,Theralase Technologies Inc

The company's efforts to transition two key therapeutics targeting Alzheimer's disease and psychiatric disorders towards full commercialization|Stephan Jackman,CEO,Alzamend Neuro Inc

Actinogen CEO Steve Goulet Discusses Promising Alzheimer's Treatment and Company Growth|Dr Steven Gourlay,CEO,Actinogen Medical

BreakBio Exploring Personalized Cancer Vaccines and AI in Cancer Treatment|Roy De Souza,CEO,BreakBio

The secret to gaining muscle after 40|Dr. Tracy Gapin,Urologist & Men’s Health Expert

one of the nation's leading providers of healthcare services|Sam Hazen, chief executive officer, HCA Healthcare

VHA is the largest integrated health care system in the United States including 172 VA Medical Centers|Neil C. Evans, MD,Veterans Health Administration

Committed to excellent standards of care|Wright Lassiter III,Chief Executive Officer, MHA

Improving Our Communities By Going Beyond Our Hospital Walls|Michael A. Slubowski, FACHE, FACMPE, President, Trintry health

CHS has been developing and operating healthcare delivery systems committed to helping people get well and live healthier|Tim L. Hingtgen, Chief Executive Officer,Community Health Systems

Great care lives here|David M. Dill,Chairman and Chief Executive Officer,LifePoint Health

We are a community built on care|Saum Sutaria, Chief Executive Officer, Tenet

PAM Health is committed to providing patients with the best care and outcomes|Anthony F. Misitano,CEO,Post Acute Medical Health

Healthcare executives face traditional problems like changes to government regulations and payment programs|Ernie W. Sadau,President,CHRISTUS Health

Business Transformation is not an easy task|Pete McCanna,CEO,Baylor Scott & White Health

Transforming Healthcare: From Sick Care to Preventative Care | Teemu Suna, CEO , Nightingale Health Oyj.

Teemu Suna on Revolutionizing Global Healthcare with Nightingale Health | Teemu Suna, CEO , Nightingale Health Oyj.

Teemu Suna on Harnessing Metabolomics to Transform Global Healthcare | Teemu Suna, CEO , Nightingale Health Oyj.

Teemu Suna on Revolutionizing Healthcare with Metabolomics | Teemu Suna, CEO , Nightingale Health Oyj.

CEO Teemu Suna Reflects on Unexpected Profitability and Future Collaborations | Teemu Suna, CEO , Nightingale Health Oyj.

Aspen Pharmacare CEO Stephen Saad is featured in the C-Suite, discussing high-level strategic insights and leadership.

Captains of Industry ABN's Bronwyn Nielsen interviews Stephen Bradley Saad, Group CEO of Aspen, about the company's strategic vision and leadership.

JSE-listed Aspen CEO Stephen Saad discusses the challenges of the pharmaceutical industry with CNBC Africa.

This week on Captains of Industry, we interview the leader of Africa's largest pharmaceutical manufacturer.

Aspen Pharmacare CEO Stephen Saad is featured in the C-Suite, providing insights into the company’s top-level strategy and leadership.

The video aims to boost interest and understanding of Tokyo's special zone, featuring an interview with Aspen Pharmacare Holdings Ltd.

CEO Scott Montgomery Highlights AHI's Progress and Upcoming Milestones | Scott Montgomery, CEO, Advanced Health Intelligence Ltd.

Michelle Xia on Akeso's Rapid Expansion and Groundbreaking Drug Development | Michelle Xia, CEO, Akeso Inc.

Michelle Xia on Akeso's Groundbreaking Progress with Cadonilimab | Michelle Xia, CEO, Akeso Inc.

Supriya Lifescience Limited Earnings Review & Business Outlook by Director Saloni Wagh | Saloni Wagh, Director, Supriya Lifescience Limited.

IPO Review of Supriya Lifescience Ltd: Insights from Saloni Wagh and Satish Wagh | Satish Wagh, Chairman, Supriya Lifescience Limited.

Supriya Lifescience MD Satish Wagh and Director Saloni Wagh on Q1 Results, Profits, and Future Expansion | Satish Wagh, Chairman, Supriya Lifescience Limited.

Supriya Lifescience IPO Opens on December 16; Aiming to Raise ₹500 Crore at ₹265-274 Price Band | Satish Wagh, Chairman, Supriya Lifescience Limited.

Christopher Gallen on Building a Biotech Business in Asia | Christopher Gallen, President, SK Biopharmaceuticals, Korea.

Dr. Saloni Wagh Discusses Supriya Lifescience's Growth Strategy and Market Leadership | Saloni Wagh, Director, Supriya Lifescience Limited.

In-Depth Conversation with Supriya Lifescience MD Satish Wagh and Director Saloni Wagh: The Journey, Legacy, and Future Vision | Saloni Wagh, Director, Supriya Lifescience Limited.

Abingdon Health CEO Chris Yates Discusses Interim Results & Growth Outlook | Chris Yates, CEO, Abingdon Health PLC.

Beleave Inc. CEO Bill Panagiotakopoulos on Expanding Cannabis Footprint and New Product Launches | Bill Panagiotakopoulos, CEO, Beleave Inc.

Beleave Inc. CEO Roger Ferreira Presents at CSE Day Spring 2016 in Toronto | Roger Ferreira, CEO, Beleave Inc.

From Cultivation to Market: Beleave Inc.'s Vision for Cannabis and Future Innovations | Bojan Krasic, CEO, Beleave Inc.

Beleave Inc. CFO Bojan Krasic Discusses Recent Developments and Expansion Plans | Bojan Krasic, CFO, Beleave Inc.

Abingdon Health CEO Chris Yates Discusses London Listing and Growth Strategy | Chris Yates, CEO, Abingdon Health PLC.

Beleave Inc. CEO Andrew Wnek on Expanding Operations and Strategic Research Partnerships | Andrew Wnek, CEO, Beleave Inc.

Florian Holzapfel on the Future of Medical Cannabis in Europe | Florian Holzapfel, CEO, Cantourage Group Se.

Philip Schetter on Cantourage's Role in the Expanding European Medical Cannabis Market | Philip Schette, CEO, Cantourage Group Se.

Marathoon Fund Management , Managing Director at Firefinch Limited

Neurizer Ltd. Chairman Daniel Peters Updates Shareholders on Strategic Developments and Financial Outlook | Daniel Justyn Douglas Peters, Chairman, Neurizer Ltd.

Voyager Life PLC's Rapid Growth and Expansion in CBD Market | Nick Tulloch, CEO, Voyager Life PLC.

Justyn Peters Addresses Adelaide Event on Urea Production Facility Progress | Daniel Justyn Douglas Peters, Chairman, Neurizer Ltd.

Voyager Life PLC's Strategic Shift: CEO Nick Tulloch on the Move from CBD to Helium | Nick Tulloch, CEO, Voyager Life PLC.

Nick Tulloch, CEO of Voyager Life PLC, on Navigating CBD Regulations and the Power of Digital Marketing | Nick Tulloch, CEO, Voyager Life PLC.

Executive Chairman Justyn Peters Discusses Project Progress and Market Challenges | Daniel Justyn Douglas Peters, Chairman, Neurizer Ltd.

Voyager Life PLC Launches UK's First Refillable CBD Products, Backed by Deputy First Minister John Swinney | Nick Tulloch, CEO, Voyager Life PLC.

Dr. B. Bhaskar Rao on Women's Health Initiatives at Krishna Institute of Medical Sciences | Dr. B. Bhaskar Rao, CEO, Krishna Institute of Medical Sciences Ltd.

Voyager Life PLC CEO Nick Tulloch Discusses Positive Interim Results and Expansion Plans | Nick Tulloch, CEO, Voyager Life PLC.

Voyager Life CEO Nick Tulloch Discusses £1.5M Acquisition of Polish CBD Facility and 2023 Outlook | Nick Tulloch, CEO, Voyager Life PLC.

Navigating the CBD Market: Insights from Voyager’s CEO | Nick Tulloch, CEO, Voyager Life PLC.

Voyager Life CEO Nick Tulloch Discusses Operations Update and Expansion into International Markets | Nick Tulloch, CEO, Voyager Life PLC.

Creating Synergy: Bausch + Lomb's CEO Brent Saunders on Fostering Academia-Industry Partnerships |Brent Saunders , CEO, Bausch + Lomb Corp.

Andreas Gerward of Stayble Therapeutics on Treatment Methods and Anticipated Q4'24 Data | Andreas Gerward, CEO, Stayble Therapeutic AB.

Reimagining the Workplace: Brent Saunders on the Permanent Shift to Remote Work |Brent Saunders , CEO, Bausch + Lomb Corp.

Andreas Gerward Represents Stayble Therapeutics at NLSDays, Sharing Developments in Life Science | Andreas Gerward, CEO, Stayble Therapeutic AB.

Brent Saunders: The Visionary CEO Behind $300 Billion in Mergers & Acquisitions |Brent Saunders , CEO, Bausch + Lomb Corp.

Andreas Gerward, CEO of Stayble Therapeutics, Shares Expertise on Clinical Trials in Eastern Europe and Industry Challenges | Andreas Gerward, CEO, Stayble Therapeutic AB.

A 25-Year Veteran Leading Bausch + Lomb's Next Chapter in Healthcare |Brent Saunders , CEO, Bausch + Lomb Corp.

Jean-Claude Maurel on Medesis Pharma’s Strategy for Controlling Inflammatory Cytokine Storms | Jean-Claude Maurel, CEO, Medesis Pharma SA.

Singapore Paincare Holdings Celebrates SBR National Business Award for DR+ Medical & Paincare | Dr Bernard Lee Mun Kam, CEO, Singapore Paincare Holdings Ltd.

Stayble Therapeutics' Andreas Gerward on Capital Raise, New Ownership, and Near-Term Milestones | Andreas Gerward, CEO, Stayble Therapeutic AB.

Jean-Claude Maurel of Medesis Pharma on Nanomicelle Technology's Promise in Alzheimer's Treatment | Jean-Claude Maurel, CEO, Medesis Pharma SA.

Revolutionizing Drug Delivery: Medesis Pharma's Breakthrough with Aonys Technology | Jean-Claude Maurel, CEO, Medesis Pharma SA.

Dr. Bernard Lee: Guiding Pain Management at Singapore Pain Care Center, Paragon Medical | Dr Bernard Lee Mun Kam, CEO, Singapore Paincare Holdings Ltd.

Jean-Claude Maurel on Medesis Pharma’s €7M IPO and Future Plans | Jean-Claude Maurel, CEO, Medesis Pharma SA.

Andreas Gerward Discusses Stayble Therapeutics' Breakthrough Product STA363, Market Scope, and Capital Strategy | Andreas Gerward, CEO, Stayble Therapeutic AB.

Dr. Bernard Lee on Fibromyalgia: Shedding Light on the Causes of Chronic Pain Disorder | Dr Bernard Lee Mun Kam, CEO, Singapore Paincare Holdings Ltd.

Jean-Claude Maurel Shares Optimism and Insights on Enhancing SME Financing | Jean-Claude Maurel, CEO, Medesis Pharma SA.

Innovating Sustainability: Insights from Berry Global's John Vassallo and Jessica Wojnicki Rodriguez at CPHI Milan | John Vassallo - VP Global R&D, Jessica Wojnicki Rodriguez - Sustainability Project Manager, Berry Global

Becoming a Fortune 500 CEO: Brent Saunders on Strategy, Success, and Scaling in Big Pharma | Brent Saunder , CEO, Bausch + Lomb corp.

Targeted Therapeutics: Patrick Lu on Sirnaomics' Innovations in RNA Interference for Critical Diseases | Patrick Y. Lu , CEO, Sirnaomics Ltd.

Global Leaders in RNAi Therapeutics: Sirnaomics’ Commitment to Patient-Centered Care | Patrick Y. Lu , CEO, Sirnaomics Ltd.

GenXone Anticipates Demand Surge in Next Pandemic Wave | Michał Kaszuba, CEO, GenXone SA.

GenXone CEO Discusses Growth Plans and NewConnect Debut Success | Michał Kaszuba, CEO, GenXone SA.

Odinwell CEO Klas Arildsson on What to Expect as Shares Debut on Spotlight Stock Market | Klas Arildsson ,CEO , Odinwell AB.

From Crowdfunding to the Stock Market: GenXone’s Roadmap to NewConnect | Michał Kaszuba, CEO, GenXone SA.

Biotech Innovator GenXone Seeks PLN 4 Million in Equity Crowdfunding | Michał Kaszuba, CEO, GenXone SA.

Anticipation Peaks as GenXone Launches on NewConnect | Michał Kaszuba, CEO, GenXone SA.

Biotalys CEO Kevin Helash on Revolutionizing Crop and Food Protection with Protein-Based Solutions | Kevin Helash ,CEO , Biotalys NV.

Argenica Therapeutics Achieves Major Milestone in Phase 2 Stroke Drug Trial | Liz Dallimore, CEO , Argenica Therapeutics Ltd.

Argenica Therapeutics Shares Insights at the ASX Small and Mid-Cap Conference | Liz Dallimore, CEO , Argenica Therapeutics Ltd.

Liz Dallimore of Argenica Therapeutics Shares Insights at 2024 TechKnow Invest Roadshow | Liz Dallimore, CEO , Argenica Therapeutics Ltd.

Argenica Therapeutics CEO Dr. Liz Dallimore Discusses Development Pathway of ARG-007 | Liz Dallimore, CEO , Argenica Therapeutics Ltd.

Argenica Therapeutics' Phase 2 Trials and Growing Share Price: A Conversation with CEO Dr. Liz Dallimore | Liz Dallimore, CEO , Argenica Therapeutics Ltd.

Improving health and well-being in our community|Robert G. Riney,President and CEO,Henry Ford Hospital

Huntsville Hospital is a community-based, not-for-profit hospital|David Spillers, chief executive officer of the Huntsville Hospital

BRASTER S.A mission is to create a healthier world|Dariusz Karolak, President, BRASTER S.A.

Krsnaa Diagnostics Ltd. IPO: A Deep Dive into the Company’s Business and Financials | Yash Mutha, Director ,Krsnaa Diagnostics Ltd.

Krsnaa Diagnostics CEO Mitesh Dave Discusses Business Strategy and Future Plans | Mitesh Dave, CEO ,Krsnaa Diagnostics Ltd.

Singular Health CEO Thomas Hanly Reflects on Successful First Quarter as ASX-Listed Company | Thomas Hanly, CEO , Singular Health Group Ltd.

Lars Minor on Newbury Pharmaceuticals’ Vision Ahead of IPO Launch | Lars Minor, CEO , Polymetals Resources Ltd.

Thomas Hanly Discusses Singular Health’s Growth and Vision in Interactive Q&A with Investors | Thomas Hanly, CEO , Singular Health Group Ltd.

Lars Minor on Newbury Pharmaceuticals’ Vision and Strategy | Lars Minor, CEO , Polymetals Resources Ltd.

CEO Thomas Hanly Reflects on His 30-Year Journey and Singular Health’s Path Forward | Thomas Hanly, CEO , Singular Health Group Ltd.

Innovative Volume Rendering Solutions by Singular Health: Transforming Medical Imaging | Thomas Hanly, CEO , Singular Health Group Ltd.

James Hill Discusses Singular Health’s Vertically Integrated Medical Business | James Hill, COO , Singular Health Group Ltd.

Innovating Pharma: Lars Minor Discusses Newbury’s Product Rollout Plans | Lars Minor, CEO , Polymetals Resources Ltd.

3D Medical Imaging: Revolutionizing Healthcare with Singular Health Group Ltd | Thomas Hanly, CEO , Singular Health Group Ltd.

Exploring Hubbster's SaaS Platform and Newbury's Pharmaceutical Growth | Lars Minor, CEO , Polymetals Resources Ltd.

James' Vision for Bridge Biotherapeutics: Advancing Pulmonary Fibrosis, Lung Cancer, and Immunology Treatments| James Lee, CEO , Bridge Biotherapeutics Inc.

Jeong-gyu Lee Shares Insights on Drug Development and Startup Success | James Lee, CEO , Bridge Biotherapeutics Inc.

CEO Spotlight: Benjamin Lightburn on Filament Health's Mission and Milestones | Benjamin Lightburn, CEO , Filament Health Corp.

Ben Lightburn Discusses Filament Health's Mission to Standardize Natural Psychedelics | Benjamin Lightburn, CEO , Filament Health Corp.

Pioneering Safe and Accessible Natural Psychedelics for Healing | Benjamin Lightburn, CEO , Filament Health Corp.

Kancera CEO Thomas Olin Discusses Kand567 Phase 2 Studies for COVID-19 and Acute Myocardial Infarction | Dr. Thomas Olin, CEO , Kancera AB.

Philogen CEO Dario Neri Introduces the Company to the City | Dario Neri, CEO ,Philogen spa.

Exploring Demoralization Syndrome Treatment with Filament Health’s Psilocybin Trials | Benjamin Lightburn, CEO , Filament Health Corp.

BioInvent CEO Explores Portfolio Strategy and Upcoming Breakthroughs | Dr. Martin Welschof, CEO , BioInvent International AB.

Thomas Olin, CEO of Kancera AB, Discusses Strategic Advances in Biopharma Innovation | Dr. Thomas Olin, CEO , Kancera AB.

Leading the Charge in the Psychedelic Movement with Filament Health | Benjamin Lightburn, CEO , Filament Health Corp.

CEO Thomas Olin on Innovation and Biopharma Advances | Dr. Thomas Olin, CEO , Kancera AB.

Filament Health Partners with Entheotech in Exclusive Licensing and Co-Development Agreement | Benjamin Lightburn, CEO , Filament Health Corp.

Filament Health and Reset Pharmaceuticals Strike Licensing Deal for Psilocybin Drug PEX010 | Benjamin Lightburn, CEO , Filament Health Corp.

Pioneering Drug Development for Inflammation and Cancer | Dr. Thomas Olin, CEO , Kancera AB.

BioInvent CEO Highlights Major Milestone and Future Goals | Dr. Martin Welschof, CEO , BioInvent International AB.

CEO Ben Lightburn Discusses Advancing Psychedelic Medicine through Natural Extraction | Benjamin Lightburn, CEO , Filament Health Corp.

Thomas Olin Highlights Kancera’s Latest Advances and Strategic Focus | Dr. Thomas Olin, CEO , Kancera AB.

Revolutionizing Healing with Naturally Derived Psychedelics | Benjamin Lightburn, CEO , Filament Health Corp.